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CHAPTER 1

Understanding liver, disease pathogenesis and basic immunology involved in acute liver
failure
Liver
The liver carries out a wide range of metabolic and biochemical functions. It is responsible
for detoxification, protein synthesis and production of digestive juices. Its other functions include
glycogen storage, gluconeogensis, cholesterol synthesis, drug metabolism, and ammonia
detoxification, synthesis of blood clotting factors, complement factors and decomposition of red
blood cells. Thus, it is an essential organ for survival.
Liver is the largest organ in vertebrates. It is made up of four unequal lobes and is supplied
blood by the hepatic portal vein and the hepatic arteries. It is the only organ capable of
regeneration in adults; after 2/3 hepatectomy normal function of liver is restored within 2-3
weeks.
Liver is functionally heterogeneous. It has a simple and uniform morphology. Liver can be
structurally divided into 1) the parenchyma, and 2) the lymphoid system. The liver parenchyma
is structured such that different and opposing functions can be carried out by the liver cells
(hepatocytes). There is a distinct metabolic zonation within the parenchyma (Gebhardt,
Baldysiak-Figiel et al. 2007). The hepatocytes are referred to as periportal (PP) or pericentral
(PC) in the compartment model of the liver. PP hepatocytes are also termed as upstream - away
from the blood capillary system - and the PC cells are called downstream hepatocytes – these are
the cells closest to the lymphoid system. These two regions are functionally distinct. Another
way to compartmentalize liver is by dividing it into three zones. The first zone is the periportal
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zone. The second zone consists of midzonal hepatocytes and the third zone is called the
pericentral region. Again, each zone consists of hepatocytes with distinct gene expression
patterns which lead to expression of proteins and enzymes for specific metabolic functions
(Gebhardt, Baldysiak-Figiel et al. 2007). Thus, liver functions are compartmentalized and carried
out by distinct subpopulation of the parenchyma (Sasse, Spornitz et al. 1992).
The lymphoid system of liver is made up of ‘sinusoids’ – the thin walled blood vessels. The
capillary network in liver consists of blood vessels delivering blood via the arterial circulatory
system and merging with portal venous blood arriving from the gut and the intestine. The
sinusoids contain a diverse population of resident immune cells such as macrophages and
dendritic cells. Other resident immune cells in liver are T cells, natural killer (NK) cells and
natural killer T (NKT) cells. The liver macrophages are called Kupffer cells (KC). KC’s are the
most abundant immune cell type in liver and are primarily responsible for removal of all
antigenic and microbial products present in intestinal blood. These immune cells are
continuously exposed to the bacterial toxins from gut. They are in a state of ‘active tolerance’,
which can be quickly changed to ‘active immunity’ during metabolic imbalance or in presence of
unknown pathogens (Crispe 2009).
Varieties of signals are secreted by the resident immune cells to attract humoral (B and T
cells) immune cells. These signals – cytokines and chemokines – attract other immune cells to
site of infection and initiate the inflammatory immune processes. Thus, the liver is a lymphoid
organ with a diverse immune cell population to maintain innate immunity.
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Figure 1.1 Cellular classification of liver.

Acute liver failure (ALF)
Introduction
Acute liver failure (ALF) is a condition characterized by development of coagulopathy
and hepatic encephalopathy in a previously healthy individual. Children are also affected by this
disease. 2000 cases are reported in US every year and 25% of the patients recover spontaneously.
However, for remaining patients the prognosis is extremely poor with death and coma being the
most frequent outcome. Treatment is aimed at removing the underlying cause of the disease
while reducing disease symptoms such as intracranial pressure. Intensive care is provided to
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patients and metabolic parameters are monitored. Liver transplantation is the only treatment for
numerous people whose liver continues to deteriorate. Mortality of ALF patients is very high.
However, with proper treatment and liver transplant short term survival of patients has increased
to 65% from 20%.
Common causes of ALF are acetaminophen overdose, viral hepatitis (A, B and E),
autoimmune hepatitis, severe alcohol intake and idiosyncratic reaction to drugs such as
tetracycline. Rapid deterioration of liver functions occurs within weeks of disease onset. Clinical
symptoms manifest over a very short period of time and correspond to the extent of liver injury.
Ultimately complete cessation of liver function occurs.
Classification:
This disease was first documented by Lucke and Mallory in 1946, when they reported
rare occurrence of fatal hepatitis (Lucke and Mallory 1946). The patients had very poor
prognosis and they often died. Lucke and Mallory classified the disease as fulminant liver failure
and acute liver failure. If liver disease development and progression occurred quickly it was
termed as fulminant liver failure and if disease development was slow then it was classified as
acute liver failure. In 1970, Trey and Davidson defined FHF as “a potentially reversible
condition, the consequence of severe liver injury, with the onset of hepatic encephalopathy
within eight weeks of the first symptoms and in the absence of pre-existing liver disease” (Trey
and Davidson 1970). In 1986 Gimson et al, defined acute liver failure and described its onset to
be within 8-24 weeks after appearance of first symptom associated with liver injury (Gimson,
O'Grady et al. 1986).
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Table 1.1. Classification terms used to characterize various forms of liver failure.
Today, FHF term is used for patients who exhibit hepatic encephalopathy within 2 weeks
of disease onset. Sub-fulminant hepatic failure is characterized by encephalopathy appearance
within 2-12 weeks of liver injury. These days ALF is used as an umbrella term to cover the
groups hyper-acute, acute and sub-acute liver failure (O'Grady and Williams 1993). Time and
etiology are important factors in disease prognosis and hence these factors are used to classify
acute failure. If the encephalopathy develops within 7 days of jaundice onset it’s termed as
hyper-acute liver failure. The majority of these patients suffer liver injury due to acetaminophen
overdose. Some patients also suffer from non-A, non-B hepatitis. If the symptoms appear within
7-28 days after jaundice onset it’s categorized as acute liver failure. If the disease development is
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very slow and occurs over time of 5 -26 weeks it’s categorized as sub-acute liver failure. Viral
hepatitis is th leading cause of acute liver failure, whereas, non-A, non-B hepatitis (with no
known viral cause) is causative of sub-acute liver failure (Gimson, O'Grady et al. 1986; O'Grady,
Schalm et al. 1993). Table 1.1 shows the current ALF classification based on the onset of
hepatic encephalopathy.
Pathology:
During ALF, hepatocyte necrosis and apoptosis are

observed within the liver

parenchyma (Lee 1993). The hepatic parenchyma collapses and numbers of viable hepatocytes
gradually decline. Regeneration is inhibited and areas of regeneration are destroyed. Portal
ductules collapse and further sites of inflammation develop. Liver cirrhosis is also observed in
alcoholic patients. In all types of ALF, inflammation is followed by massive immune cell
infiltration and subsequent release of cytokines at the site of necrotic/ apoptotic death (Lemasters
1999; Luedde, Liedtke et al. 2002).
Symptoms:
It is important to remember that all the symptoms are interconnected. The primary cause
of all the symptoms is the failing liver and diminishing liver function.
Hepatic encephalopathy and brain edema:
The yardstick of this disease classification and prognosis is the unique symptom hepatic
encephalopathy. It develops in all patients; 75 – 80% of these patients also develop cerebral
edema. The exact mechanism for hepatic encephalopathy is not agreed upon, but it is believed
that it occurs due to one or more of the following: 1) increased ammonia leading to a) increased
astrocyte glutamine and osmotic swelling and b) dysregulation of glutamate leading to
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excitotoxicity, 2) a toxic interaction between ammonia, mercaptans and fatty acids, and 3)
production of false neurotransmitters.
To elaborate on these possible mechanisms, we need to understand ammonia
homeostasis. Gut derived ammonia is detoxified by liver. It is converted into urea via glutamine
by glutamine synthetase. Ammonia incorporation into glutamine opens an amino acid formation
pathway in the body. During liver failure ammonia accumulates in the arterial blood. The
ammonia is not eliminated by liver and hence it reaches brain, where it can cross the blood brain
barrier. Ammonia concentrations in neurons and astrocytes increase and this is believed to be
responsible for neurotoxicity and convulsions (Zieve 1981). Ammonia can stimulate glutamine
synthetase in astrocytes to produce more glutamine, a powerful osmolyte that attracts water to
produce astrocyte swelling. Astrocytes in the brain try to soak up the ammonia by converting it
to glutamine via glutamine synthetase, which is present only in astrocytes. More and more
glutamine accumulates in astrocytes, leading to changes in osmolarity which is not compensated
with loss of other organic compounds. At the same time dysfunction of Na+ K+ ATPase pump
leads to water accumulation and ultimately astrocyte swelling(Poso and Pegg 1982; Blei and
Cordoba 2001; Jayakumar, Rao et al. 2006). Astrocytes are the most the abundant cell type in
brain and one-third volume of the cerebral cortex is occupied by them. Hence, the massive
swelling of astrocytes leads to brain edema and brain stem compression due to increased
intracranial pressure. Thus, pre – and post – synaptic neurons and astrocytes are responsible for
encephalopathy. However, astrocytes alone are responsible for causing brain edema (Takahashi,
Koehler et al. 1991; Blei 2001; Brusilow 2002).
Excessive ammonia also causes dysregulation in the glutamate neurotransmitter system
of brain. Glutamate is a major excitatory neurotransmitter in the mammalian brain. It is released
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by pre – synaptic neurons and it binds to its cognate receptors on the post – synaptic neurons
(NMDA receptors) and astrocytes (AMPA/ AMKA receptors). Astrocytes sit in the synaptic cleft
and are responsible for quenching excess glutamate. Astrocytes take up glutamate via GLT-1
transporter and convert it to glutamine in presence of ammonia. High levels of ammonia down
regulate the GLT-1 receptor on the astrocyte cell surface leading to prolonged exposure of post –
synaptic neurons to glutamate. Thus, the glutamate uptake is reduced and glutamate receptors on
astrocyte surface are altered by elevated peripheral ammonia, and the resulting alteration in
glutamate binding and function is considered to be one of the causes of encephalopathy
(Norenberg and Bender 1994; Brusilow 2002).
The altered mental status of ALF patients can also be attributed to toxic synergistic
interaction between mercaptans (products of enteric bacteria, which accumulate in peripheral
blood when liver fails) and ammonia along with short and medium chain fatty acids (Zieve
1981). All three alone and/ or together are considered to be responsible for convulsions and the
same has been shown by experiments done in various animal models. It is believed that during
liver failure there is a decrease in branched chain amino acids (such as leucine, isoleucine,
valine) in plasma (Fischer and Baldessarini 1976). At the same time, the other amino acids
increase in plasma, producing an imbalance in the ratio of branched chain amino acids and
aromatic amino acids (such as tryptophan, tyrosine and phenylalanine). The amino acid
imbalance coupled with increased brain glutamine leads to an increased blood flow and aromatic
amino acid deposition in brain. Aromatic amino acids stimulate the synthesis of serotonin and
the false neurotransmitter octopamine, which in turn leads to a decrease in the synthesis of
adrenaline and noradrenaline (James, Freund et al. 1979; James, Ziparo et al. 1979; Fischer 1982;
Hoyumpa and Schenker 1982). Octopamine acts as false weak neurotransmitter and along with
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inhibitory serotonin prevents actions of excitatory neurotransmitters adrenaline and
noradrenaline, thus causing neural inhibition and encephalopathy (James, Ziparo et al. 1979).
The presence of benzodiazepine agonists and altered levels of GABA also contribute towards
encephalopathy.
Metabolic complications:
One of the important hepatic functions is mobilization of glycogen stores and
gluconeogensis. Thus, the liver is a major site for insulin metabolism. During liver failure these
functions are impaired and the resulting high serum insulin levels with decreased glycogen
mobilization leads to hypoglycemia. Hypoglycemia contributes towards mental complications
observed in the ALF patients. Liver dysfunction might also cause hypophosphatemia, and acid –
base imbalance (Astrup, Prytz et al. 1980).
Acidosis is not frequently seen in ALF. However, due to hypoxia, lactate production
increases (Bihari, Gimson et al. 1985). Oxygen uptake by cells is impaired due to their inability
to extract oxygen from circulating blood. This ‘micro-circulatory dysfunction’ is responsible for
acidosis (Bihari, Gimson et al. 1985). In contrast, alkalosis is frequently observed in ALF
patients (Bihari, Gimson et al. 1985). The inability of hepatocytes to make urea from ammonia
leads to excessive ammonia and bicarbonate accumulation in systemic circulation. Also, Na+ K+
ATPase dysfunction can cause an increase in sodium reabsorption and result in hypokalemia
(Astrup, Prytz et al. 1980).
Coagulopathy:
Coagulopathy is a characteristic symptom of ALF and is used diagnostically to determine
severity of this disease. The term coagulopathy broadly encompasses two complications
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associated with ALF 1) reduction in coagulation factors and therefore delayed coagulation and
increased bleeding, and 2) reduction of fibrinolysis inhibitors.
Since the liver is responsible for production and metabolism of coagulation factors – I, II,
V, VII, IX, and X – coagulation time and bleeding is one of the easily identifiable effects of
failing liver. There is a marked prolongation of prothrombin time. Factor V has shortest half life
amongst the clotting factors and hence its synthesis is often measured to identify the extent of
impairment of coagulation factor synthesis. Platelet structure and function is altered. Platelet
numbers are also frequently reduced which results into decreased platelet aggregation and
increased adhesiveness and thrombocytopenia (Lewis, Bontempo et al. 1985). Disseminated
intravascular coagulation further exacerbates the situation (O'Grady and Williams 1986) . Anti –
thrombin III synthesis is reduced (Hallen and Nilsson 1964). All these factors lead to bleeding,
and hence, gastrointestinal and intrapulmonary hemorrhages and sepsis are common
complications observed in ALF patients.
Cardiac and pulmonary abnormalities:
Cardiac complications are rare and are dependent on other factors such as acidosis and
alkalosis, capillary leak, low osmotic pressure, arterial hypoxemia, ventilation/ perfusion
mismatch and sepsis. In ALF patients there is an elevated cardiac output and lowered systemic
vascular resistance index which causes tachycardia. Patients might also suffer from hypotension
or hypertension (especially seen in patients with encephalopathy) (Trewby and Williams 1977).
Liver and the corresponding cardiac failure lead to intrapulmonal vasodilatation and pulmonary
edema. Intrapulmonary bleeding causes further complications, such as hypoxia (Haupt, Gilbert et
al. 1985). These symptoms are similar to the abnormalities observed in sepsis and trauma
patients.
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Hepatorenal syndrome:
Kidney failure is more common in patients with drug poisoning. Acetaminophen and
amanita overdose has a direct toxic effect on renal system (Gimson, O'Grady et al. 1986). Since
renal function is associated with liver function, this liver associated syndrome is termed as
‘hepatorenal failure’. It is characterized by reduced renal perfusion. There is a reduction in urine
output and an increased excretion of serum creatinine. Decrease in renal blood flow and
circulating immune complexes harm the nephrons and cause kidney failure (Ring-Larsen 1977).
The hepatorenal failure is completely reversible and improves spontaneously once the patient’s
liver function improves or after liver transplantation. However, sepsis or long periods of
hypotension can lead to permanent kidney damage due to necrosis of renal tubules.
Infection risk:
Risk of infection is the single biggest threat to an ALF patient under treatment. Enteric
bacteria can easily translocate from gut to systemic circulation during chronic inflammation.
Moreover, due

to dysfunctional neutrophils, kupffer cells and opsonins, bacterial

(staphylococcus aureus) and fungal (candida albicans) infections are common (Rolando, Harvey
et al. 1990; Rolando, Harvey et al. 1991).
The liver houses a large number of resident innate immune cells and produces proteins of
the complement immune system (complement factor C3 and C5 are synthesized in the liver).
During ALF, KC’s are activated and they recruit additional immune cells. Multiple and
excessive cytokine secretion by the immune cells leads to immune network failure which
ultimately contributes towards increased risk of infection for ALF patients. Moreover, KC
toxicity due to its tendency to secrete tumor necrosis factor – alpha (TNF-α) has been implicated
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in various models of hepatotoxicity (Weiss 1989; Thurman, Bunzendahl et al. 1993; Leist,
Gantner et al. 1995; Rosser and Gores 1995).
Disease mechanism:
ALF is characterized by severe systemic inflammation irrespective of the presence or
absence of infection. Disease development and related complications occur due to two
consequences of failing liver. 1) Liver failure has adverse metabolic effects – all liver functions
are affected. Urea metabolism, glycogen metabolism and protein synthesis are disrupted. The
resulting effects are responsible for disease pathogenesis. 2) Liver failure is cytotoxic. Toxic
substances are not cleared from the systemic circulation and dying hepatocytes release more
toxic substances. The resultant multi – organ failure exacerbates the situation. Figure 1.2
describes the mechanism of disease progression and complications.
Endotoxemia activates numerous immune cells. Immune cell infiltration, activation of
KC and other macrophages, neutrophils, NK cells, NKT cells, dendritic cells, B and T cells leads
to secretion of different cytokines. Macrophages and lymphocytes are activated and a ‘cytokine
storm’ is generated causing inflammation. These cytokines activate multiple cytokine networks
and signal transduction pathways which are deleterious to the cells. Many of these cytokines are
capable of death pathway activation via STAT proteins or caspases. Activation of death effector
molecules with concurrent tissue and organ damage worsens liver condition. The rate of
hepatocyte death is much higher than the rate of liver regeneration and this imbalance is
responsible for failing liver (Leist, Gantner et al. 1998; Luedde, Liedtke et al. 2002). Thus, the
disease development and progression is due to inflammation.
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Figure 1.2. Flow chart showing disease mechanisms, symptoms and complications
associated with acute liver failure. Foreign agents cause activation of immune cells which
leads to inflammation. Inflammatory pathways in turn activate apoptotic and necrotic pathways
in hepatocytes. The resulting hepatic damage causes other complications associated with acute
liver failure. Other complications consist of circulatory failure, hepatorenal failure, tissue and
organ hypoxia and encephalopathy.

Immune reaction and inflammation
Introduction
As mentioned above, the massive inflammatory response mounted against the liver is
responsible for disease progression. Inflammation is the body’s physiologic response to any kind
of stress. Stress can be an infection, a chemical or biological antigen, trauma, tumor, burn, cold
or an imbalance in organ function. First, inflammation occurs at the site of injury and thereafter
spreads via the systemic circulation. Inflammation attracts various immune cells to the site of
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injury for antigen removal, and thereafter healing is initiated. The inflammatory response is
supposed to subside once systemic immune cells are involved. Thus, inflammation is supposed
to be a rapid and a temporary response – it is a method for stressed cells or tissues to attract
systemic attention and heal. However, during chronic inflammation various immune cells are
recruited which in turn secrete various cytokines. The resulting uncontrolled, persistent and
prolonged cytokine release – called a cytokine storm – causes irreversible damage to organs.
In the liver, any metabolic imbalance coupled with disturbances in liver function
homeostasis lead to the induction of ‘acute phase response’ genes within liver. Acute phase
response is a very characteristic response of the liver to infections and tissue injury. Acute phase
response is supposed to be a beneficial process. During this response, the body aims to reduce
liver metabolism. Drug metabolism is decreased and gluconeogenesis is increased. Glycogen
stores are mobilized. Lipid storage is inhibited. Essential proteins are synthesized – complement
factors, cytokines, fibrinogen are synthesized and albumin production is inhibited. Thus,
metabolism is prioritized and stringently regulated.
The acute phase response involves modulation of proteins released by the liver such that
synthesis of some proteins is decreased and some proteins are elevated. These proteins are
synthesized and secreted by the liver and they in turn function to modulate the liver metabolism.
These proteins are called acute phase proteins and are solely responsible for mounting the acute
phase response. The acute phase proteins are induced during endotoxemia, acute inflammation,
trauma and stress.
In ALF patients the acute phase response leads to uncontrolled inflammation, and some
of the acute phase proteins (esp. cytokines) harm the host system. Acute phase protein synthesis
and secretion is under the influence of cytokines TNF-α, IL-6 and IL-1 – which are amongst the

15

first cytokines to be secreted by Kupffer cells and hepatocytes. These cytokines are acute phase
proteins and their production increases during tissue injury. The cytokines trigger synthesis of
molecules such as C – reactive protein and mannose binding lecithin. These are functionally
similar to antibodies but are non specific and thus, act against a broad spectrum of irritants.
These proteins function to activate the complement pathway and opsonize pathogens for
phagocytosis by macrophages. This process gives the host system some time to mount an
elaborate and specific immune response. To describe inflammation in the context of liver failure
we need to understand 1) the immune cells, and 2) the cytokines.

Liver resident immune cells
Kupffer cells (KC)
Kupffer cells are also known as Browicz – Kupffer cells. KC’s are star shaped or
pyramidal cells consisting of a large oval nucleus and a prominent nucleolus. They originate in
bone marrow and then migrate to the liver where they develop with liver – specific – specialized
functions. These cells are functionally distinct from the alveolar, splenic and peritoneal
macrophages. These specialized macrophages are present in the lining of the liver sinusoid walls.
KC forms a bed of cells in sinusoid such that all blood passing through the liver comes in
contact with these phagocytes. They are present in between or on top of the endothelial lining of
the sinusoid capillaries with their star shaped extensions reaching out to liver parenchyma. Thus,
they are in contact with the parenchyma as well as the sinusoid system of liver (Wisse, Braet et
al. 1996). The liver is the most abundant source of macrophages and KCs form 20% of nonparenchymal cells (Naito, Hasegawa et al. 1997).
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The main function of liver macrophages is phagocytosis of gut derived antigens. They
help in red blood cell recycling. They are also responsible for maintenance of liver functions
under normal physiological and pathological conditions. Kupffer cells aid in repair of tissue
during liver injury. Their immune response includes migration to the site of inflammation,
modulation of immune response, T cell activation and proliferation, and immune surveillance
(Sun, Wada et al. 2003). They interact with neutrophils. They secrete cytokines and chemokines
which attract other immune cells to a site of infection and mount an acute phase reaction. They
can activate T cells via antigen presentation and at the same time also suppress T cell functions
by secretion of various interleukins to down regulate immune response. The cytokines secreted
by KC’s are capable of modulating hepatocyte metabolism (i.e. down regulating drug
metabolizing enzymes) during stress conditions (Monshouwer, Witkamp et al. 1996).
As mentioned earlier KC is the first line of defense against endotoxins present in the
portal blood. These cells phagocytose toxins and eliminate them. In presence of foreign antigens
or drug – induced toxins these cells go from a state of active tolerance to active immunity and
produce cytokines such as TNF-α, IL-6, oxygen – derived free radicals and nitric oxides (Decker
1990; Laskin and Pendino 1995; Wang, Wang et al. 1999). These molecules are capable of
initiating cell survival or cell death pathways.
Neutrophils (PMN)
Neutrophils are granulocytes (also referred to as polymorphonucelar neutrophils
(PMNs)). PMNs are the most important part of the innate immune response. This cell type is
most the abundant type of white blood cell (60% -70% of leukocyte (WBC) count). It has a
characteristic three – five lobular nucleus.
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PMNs are generated from various precursor cells in the blood. These precursor cells are
generated in bone marrow. Mature PMNs have a very short life of 8 -12 hours, whereas non –
active PMNs are viable in the peripheral systemic circulation for an average of 5.4 days (Pillay,
den Braber et al. 2010). Active PMNs reach various tissues and can take up specialized functions
in response to the type of infection.
PMNs are the first white blood cell response toward an infection. They are recruited
within minutes to the site of inflammation and are considered to be hallmarks of an acute
immune reaction. These cells are capable of rapid migration through the blood vessels and the
interstitial tissue in response to chemotactic signals created by chemokines such as complement
factor 5a (C5a) and leukotrine B4. PMNs arrive at the site of inflammation, engulf microbes, kill
them by production of acids (such as HClO) and superoxides – this process is called respiratory
burst – and finally the cell itself undergoes apoptosis, destroying pathogens within (Savill 1997;
Kobayashi, Yamamoto et al. 2001). Hence, neutrophils are phagocytes with extremely toxic
effects towards foreign as well host system. The programmed cell death at end of their function
is an effective way of reducing their toxic effects. Another method for PMNs to destroy
microbes/ infected cell is by secretion of granulocytes. The granulocytes consist of proteins such
as collagenase, gelatinase, lysozyme, lactoferrin, myeloperoxidase, serine protease, elastase and
cathepsins (Borregaard and Cowland 1997; Galligan and Yoshimura 2003). These granules aid
in microbe death during phogocyotsis and when released can initiate apoptosis or attract more
immune cells towards infection (Gregory and Wing 2002). Neutrophils are also capable of
secreting various cytokines that activate the macrophages and attract other immune cells.
Natural Killer (NK) cells
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NK cells are part of the innate immune system. Bone marrow derived lymphoid
progenitor cells are capable of dividing into T cells or NK cells. These lymphocytes are also
called large granular lymphocytes. NK cells are extremely cytotoxic, they can destroy tumor
cells and virus infected cells by apoptosis. Since, they are toxic to host cells; their activation is
very tightly regulated.
NK cells are activated by cytokines, Fc receptors and self expressing receptors. These
cells are mainly activated by interferons and macrophage derived cytokines. The Fc part of
antibody can bind to the Fc receptor expressed on surface of NK cell activating it (Trinchieri
1989). Other activating and inhibitory receptors are also expressed by NK cells which bind to
various endogenous and exogenous ligands of target cells. Amongst the inhibitory receptors,
major histocompatibility complex (MHC) class I plays a very important role. MHC I molecules
are expressed on the surface of host cells and they are capable of inhibiting the cytolytic activity
of NK cells.
NK cells function by inducing either apoptosis or osmotic cell lysis in target cells. These
cells secrete granzymes – which consist of proteins perforins and proteases. Perforins make pores
in cell membranes of target cells. The remaining enzymes and proteins of granzymes enter the
cell through the aqueous channels formed and then induce apoptosis or cell lysis. NK cells also
secrete cytokines and chemokines. Their response is modulated by the presence of interleukins
such as IL-2, IL-4, IL-12, IL-15 and IL-18 (Peritt, Robertson et al. 1998; Deniz, Akdis et al.
2002). The interleukin-activated cells are called ‘mature NK cells’ and are classified as NK1,
NK2 or cells resembling Th1 or Th2 (T helper subsets) cell type. This differentiation is based on
the cytokines secreted by mature NK cell in response to inflammation.
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Natural Killer T (NKT) cells
NKT cells are distinct from NK cells and T cells. They share the properties of both cell
types and hence the name. They were first indentified in mice as a subset of T cells. These cells
express the natural killer cell associated marker 1.1 and the α chain of T cell receptor (in mice)
and the β chain of T cell receptor (in humans) (Lantz and Bendelac 1994). Hence, they are also
referred to as NK 1.1 T cells in mice.
The receptors on NKT cells are capable of recognizing only the CD1d molecule
(Bendelac, Lantz et al. 1995). The CD1d molecule belongs to the CD1 antigen-presenting family
molecule and is presented by foreign lipids and glycolipids. NKT cells are not diverse but mainly
function to secrete various cytokines – predominantly IFN-γ, TNF-α, granulocyte macrophage
colony stimulating factor (GM-CSF) and interleukins IL-2 and IL-4 (Bendelac 1995; Arase,
Arase et al. 1996; Gombert, Tancrede-Bohin et al. 1996; Mendiratta, Martin et al. 1997) – to
promote and propagate or inhibit the ongoing immune response.

Major cytokines involved in ALF
Introduction
Cytokines are small proteins, peptides or glycoproteins secreted by immune cells. These
cell signaling molecules play an important role in intercellular communication. Multiple
cytokines are secreted by immune cells. Cytokines can be secreted simultaneously or
sequentially. Also, with presence of multiple immune cells, there is a diverse range of cytokines
present at the site of inflammation. These molecules are critical modulators of inflammation.
Their action is ‘local’ – i.e. they act at the site of production and, unlike immune cells, they do
not travel very far. But, although these proteins are local and are produced in extremely minute
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amounts, their effects are systemic. They are capable of forming a gradient such that other
immune cells in the vicinity can be attracted and activated.
Cytokines act as ligands. They bind to their respective cell – surface receptors on other
immune cells or target cells to produce an effect. These chemicals need to occupy only a fraction
of their receptors to produce a massive biological effect. The cytokines perform multiple actions
which are very specific. The cytokines can also activate gene transcription. Some of the gene
products are pro – inflammatory and some lead to ‘feedback inhibition’ of the cytokine. Thus,
the cytokines act synergistically or in an inhibitory manner. Some of the cytokines are
functionally redundant – and hence their actions are additive. At the same time, functionally
synergistic cytokines are limited by their receptors – the receptors of these cytokines are present
in minute amounts, and hence receptor unavailability can have a negative effect on cytokine
action. Cytokines are pleiotropic and this property plays an important role in their functional
regulation.
These small molecules function by 1) attracting other immune cells to the site of infection
(they are termed as chemokines), and 2) initiating signal transduction pathways in the target cells
to produce a “cell fate” signal which can activate either cell survival pathways or cell death
pathways.
Tumor Necrosis Factor -α (TNF-α)
Only TNF-α is discussed (other members of TNF super family are not included) here.
TNF-α is the most pleiotropic cytokine. It affects all cells. It can cause growth, differentiation,
survival, death and/or functional change. It is one of the first cytokines to be produced by cells. It
is secreted by all hematopoietic cells (i.e. cells of immune system). It is also produced by other
cell types – endothelial cells and some tissue cells. However, macrophages are believed to be the
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main producers of TNF-α. Similarly, TNF receptors (TNFR) are present on all immune cell types
and on cells of almost every tissue. TNF-α production is stimulated by pathogens, antigens and
other cytokines. TNF-α can stimulate its own production from macrophages and other tissue
cells. Its secretion and action are transient.
TNF-α is a non – glycosylated monomer of 17KDa. It is synthesized as a precursor
protein of 233 amino acid residues. A 76 amino acid sequence is cleaved from amino terminus of
the protein to activate it. The protein sequence also consists of a trans – membrane sequence of
18 residues which is 30 residues away from the amino terminus. After cleavage, the 157 amino
acid peptide is secreted and it oligomerizes to form a trimer of 51KDa. A trimer of TNF-α then
interacts with three receptors on a target cell surface, and this in turn leads to trimerization of the
receptor complex. Ligand binding leads to aggregation and cross – linking of the receptor. Cross
– linking of the receptor complex leads to its activation and initiates a downstream signaling
cascade. There are two types of TNF receptors (TNFR) called TNFR1 and TNFR2. Signaling
pathways initiated by TNFR1 and TNFR2 are shown in figure 1.3 and figure 1.4.
TNF-α is a cytotoxic and a cytostatic molecule for tumor cells (Sugarman, Aggarwal et
al. 1985). TNF-α modulates a wide range of immune functions directly – by signal transduction
and transcription of various genes – or indirectly – by promoting production and synthesis of
other cytokines which in turn lead to activation of various signal transduction pathways. It
induces synthesis of various chemoattractant molecules such as IP-10, KC and JE in specific cell
types and tissues. It can stimulate the production of IL-6, IL-1, GM-CSF, M-CSF, G-CSF (other
cytokines) and small pro – inflammatory molecules such as nitric oxide and prostaglandin E2
(PGE2) (Kilbourn and Belloni 1990). For the purpose of ALF we can categorize its functions as

22

1) effect of TNF-α on endothelium, 2) effect of TNF-α on PMN’s and 3) effect of TNF-α on
hepatocytes.
TNF-α effect on endothelium
Endothelium is a continuous monolayer of cells lining the inner wall of blood vessels. It
is impermeable to solids and cells under normal physiologic conditions. Thus, it forms a barrier
and is also the first cell type to respond to an inflammatory signal. The endothelial cells express
high affinity TNFR’s. TNF-α binding to its cognate receptors leads to changes in the actin
cytoskeleton of cells. Cells contract and change morphologically. TNF-α stimulates endothelial
cell growth and motility. Intracellular gaps are formed due to above mentioned changes. These
gaps allow immune cells to leak into the intravascular space (Beutler and Cerami 1986; Tracey,
Lowry et al. 1986). Secondly, TNF-α promotes local thrombosis. It causes a reduction in
coagulation (Tracey, Beutler et al. 1986). Endothelium surface undergoes a change after TNF-α
binding to its receptor, and as a result of which coagulation proteins are unable to assemble of its
surface (Stern, Nawroth et al. 1986). Lastly, leukocyte adherence on the endothelial surface
increases in the presence of TNF-α. Adhesion of white blood cells to the endothelium at the site
of inflammation aids in increasing the diversity of immune response. Many of TNF-α effects on
endothelium are enhanced by another cytokine IL-1.
TNF-α affects endothelial cell phenotype but does not affect its viability. These changes
lead to modulation of permeability and coagulation. Thus, in ALF, TNF-α would exacerbate the
coagulation defects and attract more white blood cells at the site of inflammation.
Effect of TNF-α on PMN’s
As mentioned earlier, neutrophil recruitment is the first response to inflammation and it
the predominant type of white blood cell. PMN’s have many TNFRs on their surface.
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Neutrophils migrate to site of inflammation and then they adhere to the endothelial surface.
Diapedesis – i.e. movement of cells from blood to tissue – occurs through the endothelial
membrane into the extracellular space. PMN’s are activated upon contact with antigens.
Thereafter, they remove the antigen and destroy themselves.
Neutrophil adhesion is increased by TNF-α. Adherence of neutrophils to the endothelium
is directly proportional to the amount of TNF-α bound to its receptor (Gamble, Harlan et al.
1985). TNF-α alone cannot cause PMN migration. Other chemokines and cytokines (such as IL8) required for chemotaxis are secreted by cells under the influence of TNF-α (Smith, Gamble et
al. 1991). TNF-α activates neutrophils and can induce the respiratory burst leading to production
of reactive oxygen species (Klebanoff, Vadas et al. 1986; Nathan, Srimal et al. 1989). It
increases phagocytosis and primes them for ‘antibody dependent cell mediated cytotoxicity’
(Shalaby, Aggarwal et al. 1985). However, the above two effects are also modulated by the
active oxygen species produced by respiratory burst. And so, these effects can be directly and
indirectly attributed to TNF-α.
Thus, TNF-α is involved in all stages – from neutrophil recruitment to function. TNF-α in
conjunction with G-CSF and GM-CSF has an effect on hematopoietic progenitor cells. It can
directly modulate B-cell and T-cell production in the bone marrow and thymus. In ALF, the
effects of TNF-α on neutrophils can be held responsible for necro-apoptotic death of
hepatocytes.
Effect of TNF-α on liver
Since liver has the largest resident population of macrophages – kupffer cells – it
produces abundant amounts of TNF-α. Small amounts of TNF-α transcript are detectable in
normal hepatocytes due to pathogens present in the systemic circulation (Tovey, Content et al.
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1988). Transcript levels increase sharply in response to tissue trauma. Since liver cells also
produce acute phase proteins, hepatocytes can also produce TNF-α (which is an acute phase
protein). In turn, TNF-α increases production of acute phase proteins. Thus, liver is a source as
well as a target of TNF-α.
TNF-α’s main effect on liver is to increase the synthesis of acute phase proteins
(Mortensen, Shapiro et al. 1988). These effects are mediated directly and indirectly by it. TNF-α
binding to its receptor induces transcription of genes which lead to synthesis of pro –
inflammatory molecules. It leads to IL-6, IL-1, and complement C3, fibrinogen and fibronectin
synthesis (Andus, Geiger et al. 1988; Bertini, Bianchi et al. 1988). The acute phase proteins and
TNF-α in particular, reduce drug metabolism (Renton 1986). During stress, the capacity of liver
to metabolize drug and certain substances is changed. Synthesis of proteins such as albumin is
decreased and lipid metabolism changes. TNF-α reduces cytochrome P450 and dependent
enzymes, thus directly decreasing drug metabolism (Ghezzi, Saccardo et al. 1986). TNF-α
increases acetyl CoA carboxylase and fatty acid synthetase thereby directly increasing de novo
fatty acid synthesis (Grunfeld, Verdier et al. 1988; Feingold, Serio et al. 1989). At the same time
it inhibits lipoprotein lipase and decreases lipid storage (Enerback, Semb et al. 1988).
TNF-α binding to its receptors causes cytolysis of infected/ damaged liver cells. Cytolysis
aims to prevent release of toxic liver products into circulation. TNF-α is a key regulator of
leukocyte migration and adhesion to liver endothelial cells. It induces IL-8 secretion which
increases neutrophil and leukocyte adhesion. TNF-α stimulates secretion of IL-1 and IL-6 and
many of its effects are mediated via these two cytokines. Lastly, TNF-α is the most important
factor in septic shock and is one of the cytokines capable of hepatotoxicity – i.e. hepatocyte
death via necrosis and/ or apoptosis.
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Interleukin – 6 (IL-6)
IL-6 belongs to a big group of cytokines (IL-6 super family) and only IL-6 has been
described in this introduction. IL-6 is another pleiotropic cytokine produced by almost all
immune cells and by some tissue cells. IL-1, TNF-α and bacterial endotoxin – LPS – can
stimulate IL-6 production (Gauldie, Richards et al. 1987). It is not constitutively expressed and
hence, stimulation leads to an increase in its transcript levels and protein synthesis. Macrophages
and monocytes are the first and primary producers of this cytokine. Other cells, such as epithelial
cells, endothelial cells, B – and T – cells, astrocytes and microglia secrete IL-6 under the
influence of appropriate stimuli (i.e. in presence of IL-1/ TNF-α) (Frei, Malipiero et al. 1989;
Luger, Schwarz et al. 1989; Hirano, Taga et al. 1990).
IL-6 is a 212 amino acid protein. It is glycosylated in two places and has four cysteine
residues. It is synthesized as a precursor protein with a 22 amino acid leader sequence. The
active form of IL-6 is a 185 residue peptide and has a mass of 21KDa. Monocytes are capable of
secreting five isoforms of this cytokine with differing glycosylation sites and different molecular
mass. IL-6 receptor is expressed in numerous tissues and immune cells, but very few or none are
present on macrophages. Its receptor is a trans – membrane protein with an extracellular and an
intracytosolic domain. The receptor itself has no kinase activity – i.e. it has no tyrosine kinase or
serine/ threonine kinase activity. It associated with glycoprotein 130 (gp130) protein. gp130 is
also a trans – membrane protein and it is present in all tissue and organs. Ligand binding causes
receptor homo dimerization. gp130 dimerization activates tyrosine kinase, and subsequent
phosphorylation of tyrosine residues occurs. The tyrosine residues are present on the intracellular
domain of the protein and their phosphorylation is responsible for activation of downstream
signaling cascade. The soluble IL-6 receptor is formed by cleavage of extracellular portion of IL-
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6 receptor. The soluble receptor is capable of ligand binding and gp130 association. The effects
of soluble receptor are also mediated by gp130. The soluble receptor has a regulatory function
and is important for migration of IL-6 signaling. The biological functions of IL-6 are listed
below.
Effect of IL-6 on immune response
IL-6 has an immunomodulatory effect on B cells, T cells, cytotoxic T lymphocytes (CTL)
and NK cells. It promotes B cell maturation and differentiation (Kishimoto 1989). It does not
affect B cell proliferation but increases IgM, IgG and IgA antibody production (Taga, Kawanishi
et al. 1987). IL-6 induces differentiation of mature and naïve T – cells into CTL with the aid of
IL-2. It also induces maturation of T – cells and CTL (Okano, Suzuki et al. 1989). IL-6, like
TNF-α, primes PMN’s for respiratory burst and increases NK activity (Luger, Schwarz et al.
1989). IL-6 is an inhibitor of TNF-α and IL-1 secretion (Schindler, Mancilla et al. 1990). Lastly,
GM-CSF belongs to IL-6 super family. IL-6 is homologous to GM-CSF and can perform similar
functions, as a result of which it can modulate hematopoiesis (Leary, Ikebuchi et al. 1988).
Effect of IL-6 on liver
IL-6 is an acute phase protein and it increases production of other acute phase proteins
(Andus, Geiger et al. 1988). Like TNF-α, it reduces production of albumin and transferrin during
inflammation (Andus, Geiger et al. 1988). It reduces drug metabolism and is a modulator of
glycosylation of liver secreted acute phase proteins. One of the key impacts of IL-6 is its ability
to modulate extracellular matrix integrity. It is known to affect matrix metalloproteinase (MMP)
which degrades collagen. IL-6 increases TIMP 1 – a MMP inhibitor – production and causes an
imbalance in MMP and TIMP 1 levels (Sato, Ito et al. 1990). IL-6 also increases α1 – antitrypsin
– a protease inhibitor of neutrophil elastase. The signal transduction pathway of gp130 (figure
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1.5) leads to activation of various cell survival and anti – inflammatory genes (Tilg, Dinarello et
al. 1997). IL-6 is considered to be hepato – protective because of its above mentioned effects.
However, increasing evidence of its toxicity is emerging.
Interferon – γ (IFN-γ)
IFN-γ is a potent cytokine. Its expression is very tightly regulated. It is produced by only
T – cells and NK cells. It is produced by both CD8+ and CD4+ T cell types (Th0 and Th1 – T
helper cells can produce the cytokine) (Celis, Miller et al. 1986; Mosmann, Cherwinski et al.
1986; Yamada, Meager et al. 1986). Antigen presenting cells bearing major histocompatibility
complex - MHC class II bind to CD4+ T lymphocytes to stimulate IFN-γ. Secondly, MHC class
I bearing target cells can initiate IFN – γ expression by binding to CD8+ CTL cells. Lastly,
activated macrophages secrete TNF-α which activates NK cells and cause IFN-γ production. It
has a minor antiviral activity. Its main function is immunomodulation.
IFN-γ is synthesized as 166 amino acid precursor protein with a 23 amino acid secretory
signal. The cleaved 146 amino acid protein is glycosylated at 2 places. It forms a dimer and each
subunit is of 20KDa or 25KDa. IFN-γ is distinct from IFN-α and IFN-β. This cytokine is
secreted immediately after its synthesis.
IFN-γ receptor is present on all cell types except mature erythrocytes. The receptor
consists of α and β chain and are identified as IFN – γR1 (α chain receptor) and IFN – γR2 (β
chain receptor). R1 is glycosylated and is essential for ligand binding. It is a trans – membrane
protein and it dimerizes in presence of IFN-γ dimer. Thereafter, R2 binds to R1. R2 is essential
for receptor function. Ligand binding activates tyrosine kinases and recruits latent cytosolic
transcription factors. IFN-γ mediates its effects by signal transduction via the above mentioned
complex as shown in figure 1.6. IFN-γ signaling pathway leads to activation of genes that
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ultimately determine the cell’s fate. Additionally, transcription of early response and late
response pro – inflammatory genes is initiated to propagate and sustain the immune response.
Following sections describe the immunomodulatory effects of IFN-γ in detail.
Effect of IFN – γ on B and T – cell
IFN-γ inhibits B – cell growth. It specifically increases IgG2a production and decreases
IgG2b, IgG1, IgG3 and IgG E production (Snapper and Paul 1987; Bossie and Vitetta 1991). It
modulates T – cell growth and differentiation. Its growth-promoting effects on T cells are
responsible for its cytotoxicity. IFN-γ is the only cytokine with an ability to regulate MHC class
II genes (Blanar, Boettger et al. 1988; Amaldi, Reith et al. 1989). MHC class II genes need
several hours for activation and are therefore involved in the late response of IFN-γ. MHC class
II molecules are essential for functions of T cells, T helper cells, B cells and macrophages. Thus,
this cytokine has long lasting effects. IFN-γ also stimulates MHC class I gene transcription.
MHC class I and II molecules are essential for antigen presentation and subsequent activation of
T cells.
Effect of IFN-γ on macrophages and NK cells
IFN-γ activates resting macrophages and NK cells. IFN-γ induced stimulation of
macrophages elicits higher amount of TNF-α production – there is a fivefold increase in TNF-α
production. Thus, the production of IFN-γ by NK cells leads to a positive feedback loop for
TNF-α production (Unanue 1997). Macrophages secrete small amounts of TNF-α on antigen
exposure. TNF-α activates NK cells in the vicinity. NK cells being part of innate immune system
are capable of generating large amounts of IFN-γ which activate other macrophages to secrete
large amounts of TNF-α and this initiates a cascade of TNF-α and IFN-γ. The resulting huge

29

amounts of TNF-α are responsible for cell toxicity and can cause TNF-α induced shock (e.g.
sepsis and toxic shock).
TNF-α and IFN-γ synergistically act to increase the expression of adhesion molecules on
endothelial cell surface to aid cell migration and amplify immune response. IFN-γ causes
secretion of reactive oxygen species and hydrogen peroxide from macrophages, thereby
destroying antigens. It also induces the production of nitric oxide synthetase (iNOS) in
macrophages. iNOS is responsible for production of nitric oxide (NO). The anti – tumor, anti –
viral and anti – parasitic actions of IFN-γ can be attributed to NO (Karupiah, Xie et al. 1993).

Signal transduction pathways
Signal transduction pathway initiated by TNF-α
TNF-α mediated signaling is not initiated by the ligand binding to its cognate receptors
but it is initiated by receptor trimerization which follows ligand binding. Also as mentioned
earlier there are two types of TNF-α receptors – TNFR1 and TNFR2. These receptors function
together or individually for activation of different pathways. Receptor activation leads to
activation of cell death or cell survival pathway.
Death signaling and caspase cascade
TNFR1 and Fas receptor (which belongs to TNF receptor super family) are the only TNF
family receptors capable of initiating apoptosis. The cytoplasmic domain of these trans –
membrane receptors consists of a 80 amino acid sequence called ‘death domain (DD)’. This
sequence of amino acid has an interface for protein – protein interaction. Fas associated death
domain (FADD) and TNFR1 associated death domain (TRADD) also contain ‘death domains’
which interact with receptor DD. TRADD binds to DD of TNFR1. Thereafter, FADD binds to
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the DD of TRADD or it binds to DD of Fas receptor and the resulting molecular complex
recruits various caspases. FADD has a death effector domain (DED). Caspases with DED motifs
are cleaved by FADD triggering their activation. Caspase-8 has two intrinsic DED which leads
to cleavage of pro-caspase-8 and its subsequent activation.
Active caspase-8 can directly activate the caspase cascade. Also, caspase-8 can activate
mitochondrial death pathway by cleavage of protein called p22 Bid to form p15 Bid. p15 Bid
which translocates to the mitochondrial membrane and induces release of cytochrome C (Cyt C).
Cyt C, apoptotic protease activating factor – 1 (Apaf -1) and pro-caspase 9 form a complex
called “apoptosome” which cleaves pro-caspase 9 to form caspase 9. Active caspase 9 cleaves
other pro-caspases and initiates the caspase cascade. By either method, activation of death
effector caspases such as caspase-3 occurs which induces cellular apoptosis. TNFR1 and Fas
receptor stimulated death pathways are shown in figure 1.3.
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Figure 1.3. Cell death pathway activated by TNF. The signal transduction pathway leading to
cell death are activated via TNFR1 and FasL. Death domains of recruited Fas associated death
domain (FADD) and TNFR1 associated death domain (TRADD) directly activates caspases or
via mitochondrial death pathway to initiate apoptosis.

Cell survival signaling
TNF-α induces cell survival via activation of the NF-κB pathway as shown in figure 1.4.
TNFR1 and TNFR2 are involved in activation of cell survival pathway. Receptors trimerize in
presence of TNF-α. TRADD binds to active TNFR1 complex and thereafter, TNF receptor
associated factor (TRAF2) binds to TRADD. TRAF2 can bind directly to TNFR2. The receptor
and TRAF2 complex (with or without TRADD) phosphorylates NF-κB inducing kinase (NIK)
and activates NF-κB (nuclear factor kappa light – chain – enhancer of activated B cells). Inactive
NF-κB is associated with the inhibitory protein IκB kinase (IKK) as a heterodimer complex. IKK
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is made up of IKKα and IKKβ subunits. Active NIK phosphorylates IκB – α. This leads to its
proteosomal degradation. Remaining IKK complex dissociated from NF-κB and it becomes free
to translocate to the nucleus and initiate transcription of cell survival genes.

Figure 1.4. The signal transduction pathways leading to cell survival are activated via
TNFR1 and TNFR2. TNF receptor associated factor (TRAF2) poshporylates proteins of NF-κB
pathway. Activated NF-κB translocates to the nucleus and activates gene transcription of cell
survival and anti-inflammatory genes.

Signal transduction pathway initiated by IL-6
The signaling pathways of IL-6 are activated via the gp130 molecule’s association with
IL-6 receptor. gp130 is capable of recruiting Janus kinase family members (JAK). The tyrosine
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kinases of JAK family (JAK1, JAK2 and TYK) phosphorylate various tyrosine residues on
gp130. Thus, activated domain of gp130 is responsible for activation of transcription factors –
the STAT proteins. STAT’s in turn are responsible for transcription of IL-6 response element
genes. STAT – signal transducers and activators of transcription – are transcription factors which
regulate various aspects of cell cycle. STATs bind to promoters of cytokine inducible genes and
initiate transcription of cytokines/ proteins that lead to cell survival, death, differentiation or
proliferation.
gp130 homodimerizes, and its interaction with JAK leads to its association with STAT
family members. The tyrosine residues on latent cytosolic STATs are phosphorylated. Activated
STAT isoforms form homodimers or heterodimers. STAT dimers translocate to the nucleus, bind
to target DNA and activate transcription. STAT’s are well characterized initiators of apoptosis.
However, IL-6 response element binding protein causes the recruitment of acute phase response
factor STAT3. STAT3 homodimerization or heterodimerization with STAT1 activates genes that
are predominantly anti-apoptotic. The mechanism of IL-6 associated signal transduction pathway
is shown below in figure 1.5.
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Figure 1.5. Signal transduction pathways activated by IL-6. IL-6 binds to gp-130 receptors.
gp-130 phosphorylates Jak proteins and thus activates STAT1 and STAT3. Homodimers and
heterodimers of STAT1 and 3 translocate to nucleus and initiate gene transcription.

Signal transduction pathway initiated by IFN-γ
IFN-γ binding to its receptor activates two tyrosine kinases – JAK1 and JAK2. This
receptor is unique because it requires both the α and β chain of receptor for function. The α chain
receptors bind to IFN-γ and dimerizes. JAK1 is recruited near the receptor – one for each subunit
of the α chain of receptor dimer. JAK2 binds the β chain receptor and gets associated with JAK1.
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Figure 1.6. IFN-γ activated signal transduction pathways leads to activation of STAT1.
IFN-γ binding to receptor IFNγR1 leads to recruitment of JAK1. Then IFNγR2 then associated
with IFNγR1 and JAK2 associated with IFNγR2. JAK activate STAT1 and STAT1 homodimers
translocate to cell nucleus and bind to Interferon-γ activated sites (GAS) promoters on DNA.
GAS promoter initiate transcription of IFN-γ induced genes, several of which induce apoptosis.
Once the αβ receptor chains are in close proximity JAK1 and JAK2 form an active
complex which is capable of activating STAT’s. IFN-γ is known to specifically activate STAT1.
Two cytosolic STAT1 molecules dock at receptor associated JAK phosphorylation site.
The JAKs subsequently phosphorylate STAT1 proteins. STAT1 then dissociates from JAK
complex and forms homodimers which translocate to the nucleus. A schematic representation of
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IFN-γ and STAT1 pathway is shown in figure 1.6. STAT1 binds to interferon-γ activated sites
(GAS) on DNA. The Interferon-γ activated sites (GAS) are promoter elements on DNA that
initiate transcription of IFN-γ induced genes. Amongst different gene products, STAT1 functions
to increase transcription of apoptosis inducing proteins.

Conclusion
ALF – acute liver failure – is a condition wherein multi organ failure follows liver injury.
Medical conditions such as encephalopathy, hepatorenal failure, cardiovascular overload and
pulmonary complications result from failing liver and are responsible for ALF associated
mortality. The main reason for deterioration of patient condition is sepsis and generation of an
uncontrolled immune response. Inflammation coupled with acute phase reaction leads to
generation of cytokines which reduce liver function, cause a metabolic overload and harm liver
and other tissues by activating apoptosis in cells.
Immune response is central to disease progression in ALF. Resident immune cells – KC,
NK and NKT cells – recruit other immune cells (such as PMN’s, B – cells and T – cells) during
inflammation. KC, NK, NKT and PMN’s phagocytose pathogens and thereby remove antigens
from liver. They secrete cytokines and chemokines to attract other immune cells. These cells
secrete various cytokines, key amongst which are TNF-α (secreted by KC, NK and hepatocytes);
IL-6 (secreted by KC) and IFN-γ (secreted by NK, NKT and T – cells). Thereafter, cytokines
activate gene transcription of cell survival or cell death proteins via various signaling
transduction pathways.
It is important to understand the immune mechanisms involved in acute liver failure.
Disease pathology is the direct result of complicated immune network reactions in ALF. Solving
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this network to identify targets which could be used therapeutically is essential to developing
treatments for ALF. The results of these studies might also be applied to other diseases where the
immune system harms host organs by excessive and uncontrolled cytokine production.
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CHAPTER 2
Glutamine synthetase as a potential therapeutic target and use of methionine sulfoximine to
understand mechanisms involved in progression of acute liver failure
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glutamate in a mouse model of ALS.
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Introduction
Acute liver failure (ALF) mouse model
Liver injury resembling acute liver failure (ALF) can be induced in animals by
administration of low doses of E. coli lipopolysaccharides (LPS) with the sugar D-galactosamine
(D-GalN; 2-amino-2-deoxy-D-galactose). This model mimics immunological and biochemical
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symptoms of ALF. D-GalN was initially administered as six sequential intraperitoneal,
intravenous and/or subcutaneous injections (Decker and Keppler 1972). Later, a single injection
of high dose of D-GalN was found to be equally effective in causing liver damage (Scharnbeck,
Schaffner et al. 1972). Injection of low dose of LPS along with D-GalN is essential for the injury
to be liver specific.
Keppler and Decker initiated a detailed study on the toxicity of galactosamine on liver.
Morphologic and biochemical changes occurring due to non-lethal doses of D-GalN showed that
liver functions are impaired and protein synthesis was inhibited. Hepatic glycogen stores
decreased and various hepatic function marker enzymes such as alanine transaminase (ALT) and
aspartate transaminase (AST) were elevated. Total billirubin values were also higher than normal
(Decker and Keppler 1972). These markers are indicators of liver health and liver functions.
Enzyme changes observed in the animal model closely resembled the liver injury symptoms of
ALF patients.
D-GalN is a hepatotoxic agent. LPS administration along with D-GalN causes generation
of an immune response characteristic of this disease. Thirty minutes post disease induction,
nucleolar fragmentation was observed. Amino acid uptake was unaffected but protein synthesis
was inhibited. Changes occurred in the polyribosomal profile (Shinozuka, Farber et al. 1973).
Liver readily takes up D-GalN and metabolizes it. During metabolism of D-GalN, UDP – GalN
is formed by the non-specific enzyme galactose - 1 – phosphate: UDP – glucose
uridyltransferase. UDP – GalN cannot serve as an uridylate donor during translation. Continuous
formation of UDP – GalN traps uridine phosphates and depletes the supply of uridilylate donors
such as UTP, UDP and UMP. Thus, RNA synthesis was inhibited. Lactate – pyruvate and ATP –
ADP ratios were found to be normal. However, adenine nucleotide levels were reduced (Decker
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and Keppler 1974; Konishi, Shinozuka et al. 1974). Further elucidation of this model has
indicated that morphologic liver changes occur after RNA synthesis inhibition.
High doses of LPS alone (in rodents) cause massive inflammation and release of
cytotoxic molecules leading to severe sepsis and multi – organ failure. However, the use of a low
dosage of LPS with D-GalN leads to the generation of an immune response which is
predominantly directed towards liver. Initially, other organs are not affected. Later, multi organ
failure occurs. The damage is limited to liver and can be completely reversed by administrating
uridine within 3 hours of disease induction (Galanos, Freudenberg et al. 1979). Thus, LPS/ DGalN model of liver failure mimics the hepatotoxicity observed during liver injury. This model is
not specific to any type of drug overdose, but its pathogenesis and symptoms closely resemble
those of broad – spectrum liver diseases.
Glutamine Synthetase
Glutamine synthetase (GS, also known as γ-glutamyl: ammonia ligase; EC 6.3.1.2) is an
important enzyme in nitrogen metabolism. This enzyme binds glutamate and ammonia in
presence of divalent cations (such as magnesium and manganese) and adenosine triphosphate
(ATP), and converts it to glutamine (Eisenberg, Gill et al. 2000). The reaction is shown in figure
2.1. GS is the only enzyme in body for synthesizing glutamine.
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Figure 2.1. Glutamine synthetase catalyses reaction between glutamate and ammonia to
form glutamine. γ-glutamyl phosphate intermediate is formed during the reaction. ATP and
magnesium ions are required for this reaction to proceed.

There are three types of GS and each type is structurally different. GS type I and III are
found in prokaryotes, but eukaryotes mainly express type II GS (Eisenberg, Gill et al. 2000).
Each type of GS consists of two active sites – one for an amino acid and the second for
nucleotide (Hibi, Nii et al. 2004). The amino acid binding site is highly preserved, whereas the
nucleotide binding site varies across organisms. Additionally, there are three metal ion binding
sites for enzyme stability and catalytic activity (Pesole, Gissi et al. 1995). Mammalian GS is
homologous across species in terms of amino acid composition, structure and molecular weight.
One key feature of this enzyme in mammals is that it is not modified post-transationally, as is the
case for the E. coli glutamine synthetase (Stadtman, Shapiro et al. 1968; Stadtman 2001).
In mammals, GS is made up of 12 identical subunits of 50KDa each (Meister 1985).
These subunits are arranged in two identical hexagonal structures that face each other. The rings
are composed such that a channel is formed in each subunit. The wall of this bi – funnel (one
ring in each subunit) is made up of six four – stranded β sheets. The β sheets are arranged to
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form anti – parallel loops within the subunit structure. Hydrogen bonding and hydrophobic
interactions hold the subunits together such that the C-terminus of GS is inserted into the
hydrophobic core of the ring shaped structure. The hydrophilic N-terminus remains exposed to
solvent. A cartoon of enzyme structure and its substrate binding sites is shown in figure 2.2.

Figure 2.2. A cartoon of glutamine synthetase structure is shown above. GS is made up of 12
identical sub units arranged as two hexamers. The hexagonal structure is made up of anti parallel
β – sheets. A bi-funnel is formed within the hexagon. The active site of enzyme is in the bifunnel and substrate binding site is within it. ATP binds to the active site on the top and
glutamate and ammonia bind to the active site on the bottom of the bi-funnel.
Each active site is in the bi – funnel. The active site consists of distinct substrate binding
pockets. ATP binds to the top of the funnel structure and is on the external surface of GS.
Glutamate and ammonium bind at the bottom of the active site. Two sites for binding of divalent
cations are present inside the funnel. These cations stabilize the structure and carry out transfer
of phosphate from ATP to glutamate. One cation binding site is in proximity to each of substrate
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binding site. The reaction takes place via formation of ADP – γ glutamyl phosphate complex.
First ATP is hydrolyzed and phosphate transferred to glutamate to form an acyl intermediate of
ADP and glutamate. ADP and Pi do not dissociate from the enzyme until ammonia binds to the
carboxy group of glutamate. ADP stabilizes the γ glutamyl phosphate bound form of enzyme via
conformational changes. This promotes ammonium ion binding to the polar solvent exposed
binding site of the enzyme. Thereafter, ammonium attacks the ADP – γ glutamyl phosphate
complex to form glutamine. The resulting ADP and glutamine then leave the complex.
GS can also carry out other reactions. If hydroxyl amine binds to GS instead of
ammonium, γ – glutamylhydroxamate is formed. This reaction is exploited to assay GS activity
in tissue extracts. The concentration of ammonium determines the fate of the acyl intermediate.
There is a substrate binding competition between ammonium and water molecule. If water enters
the active site, the hydroxyl group attacks the intermediate to reform glutamate. This ωamidation reaction is reversible and the enzyme is tightly regulated by its substrates, products
and other amino acids which are synthesized from glutamine. GS exhibits cumulative inhibition.
i.e. each inhibitor reduces the activity of the enzyme, even when other inhibitors are bound to the
enzyme at saturating levels . Glutamine formed by GS is a source of nitrogen in the biosynthesis
of tryptophan, histidine, carbamoyl phosphate, glucosamine-6-phosphate, cytidine triphosphate
and AMP. GS is negatively regulated by all the above mentioned products and also by alanine
and glycine.
GS is present in various tissues – mainly liver, brain and kidneys. Brain and liver
isoforms of GS can be octamers. Muscle, lung and immune cells also express GS to fulfill their
glutamine requirements and to convert ammonia into a non – toxic form for transport to liver.
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GS and liver
The distribution of GS in liver is unique. GS is a cytoplasmic enzyme in liver. It has
homogenous distribution within a cell which expresses it. Glutamine Synthetase is expressed
exclusively in a small sub population of pericentral hepatocytes (PC). GS is present only in the
PCs which surround the central veins in the liver – hence, it is termed as a perivenous enzyme
(see figure 2.3). Urogenesis (urea formation or ureagenesis) and glutamine synthesis - i.e.
ammonia detoxification pathways are compartmentalized in liver. These two functions are done
by upstream

periportal (PP) and downstream pericentral (PC) hepatocytes respectively

(Gebhardt, Baldysiak-Figiel et al. 2007). GS zonation leads to an unequal distribution of function
within the hepatocytes. 94% of zone 1, 2 and 3 hepatocytes express enzymes involved in urea
formation. 8% of cells function to synthesize glutamine and express GS. 2% overlapping cells
can perform both functions (Gebhardt, Lindros et al. 1991). This segregation of enzymes and
function enables the liver to efficiently remove ammonia from portal circulation. At the same
time, liver plays a major role in glutamine homeostasis by removing or adding glutamine to the
blood circulation (Watford, Chellaraj et al. 2002).

45

Figure 2.3. Glutamine synthetase distribution in liver tissue. Immunohistochemically stained
tissue for liver glutamine synthetase is seen here. The tissue section shows distinct cells. The
lightly stained cells are periportal hepatocytes (upstream cells) which do not express GS. In the
center of this section a small venule is observed. Cells surrounding the vein are pericentral
hepatocytes (downstream cells). The downstream cells express GS and these are called
perivenous hepatocytes.

The liver is not a major producer of glutamine, but liver GS has the highest specific
activity amongst all organs due to a high glutamine turnover (Cooper, Nieves et al. 1987;
Gebhardt and Reichen 1994). This high GS specificity coupled to excessive glutamine (i.e.
substrate) turnover occurs due to the “feed – forward – activation” of the glutaminase enzyme. In
PP cells, glutaminase breaks down glutamine (Haussinger 1990., Low et al., 1993) and glutamate
is released into the blood. Simultaneously, ammonia is continuously fixed into carbamyl
compounds by upstream hepatocytes.

As blood passes downstream, the portal ammonia

concentration declines such that urea formation (urogenesis) can no longer occur effectively. At
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this point, the downstream PCs scavenge the remaining ammonium ions to synthesize glutamine.
The schematic of glutamine – glutamate cycle occurring in hepatocytes is shown in figure 2.4.
This newly synthesized glutamine overcomes the loss occurred during glutamine breakdown by
PPs, thus, maintaining plasma glutamine levels of 0.8mM in the portal circulation. This
hypothesis was supported by the work of Geerts et al. They showed that glutamate concentration
decreases in blood collected from upstream to downstream sections of liver but is restored to its
normal levels at the end point of portal circulation (Geerts, Jonker et al. 1997). Thus, the nitrogen
metabolism and glutamine homeostasis is closely interrelated by GS in liver.

Figure 2.4. A schematic diagram of glutamine – glutamate cycle in liver is shown above.
Upstream hepatocytes contain enzymes for urea formation and glutamine breakdown. They take
up glutamine, break it down to form glutamate and release it into the blood stream. After urea
formation, residual ammonia is scavenged by downstream hepatocytes containing glutamine
synthetase. Glutamate from blood stream is also taken up by these downstream pericentral
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hepatocytes and is combined with ammonia to form glutamine. Glutamine formed is released
back into blood stream.

Glutamine Synthetase as a potential drug target:
GS is being increasingly studied in immunology due to the immune cell’s requirement of
glutamine for cell proliferation, differentiation and cytokine production (Karinch, Pan et al.
2001; Newsholme 2001). It is well established that glutamine levels influence macrophage
function and cytokine release in tissue culture, and long-term dietary changes can modify
immune function in living animals (Newsholme 2001; Li, Yin et al. 2007; Roth 2007). A
detailed study of the effects of glutamine concentrations on T cell differentiation has divided the
response into an early glutamine-independent phase and a later glutamine-dependent phase
(Hörig, Spagnoli et al. 1993). Also, dietary glutamine has been known to enhance cytokine
production in macrophages and increases T cell responsiveness (Kew, Wells et al. 1999; Rogero,
Tirapegui et al. 2008).
Interestingly, only 5% of the hepatocyte population contains glutamine synthetase
(Gebhardt and Mecke 1983; Häussinger, Stoll et al. 1989). 9% of the liver GS activity is
localized in kupffer cells. Also, kupffer cells constitutively express GS and possess higher GS
mRNA levels as compared to parenchymal liver cells (Bode, Peters-Regehr et al. 2000).
Lastly, as mentioned in the introduction, hyperamonemia is observed in ALF patients.
Due to failing liver and dying hepatocytes, imbalance in ammonia metabolism occurs. Excess
ammonia produced in liver is taken up by astrocytes and converted to glutamine by GS enzyme.
Astrocytes then swell up due to glutamine accumulation. This causes an increase in intracranial
pressure in brain stem leading to brain edema (Takahashi, Koehler et al. 1991). The
hyperammonaemia resulting brain edema in rats is similar to brain swelling during hepatic
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encephalopathy of ALF patients (Groflin and Tholen 1978).

In a rat model of

hyperammonaemic encephalopathy, brain swelling is completely prevented by GS inhibition
(Takahashi, Koehler et al. 1991; Brusilow 2002; Tanigami, Rebel et al. 2005).
MSO
L-Methionine Sulfoximine (MSO) is an irreversible inhibitor of Glutamine Synthetase
(GS). MSO is one of the most potent GS inhibitors with as Ki of 1.1µM. The ability of MSO to
inhibit GS was first reported in 1952 (Pace and Mc 1952). It also inhibits γglutamylcysteinesynthetase, the first step in glutathione synthesis. MSO inhibits γglutamylcysteinesynthetase at concentration of 0.2-2.0 mM.
MSO is a modified form of the amino acid methionine (figure 2.5). Mechanistically,
MSO competes with glutamate for binding in the amino acid pocket of GS. In the presence of
ADP and Mg2+, enzyme phosphorylates MSO. The phosphorylated form of MSO – methionine
sulfoximine phosphate binds irreversibly to the enzyme and inhibits it (Ronzio, Rowe et al.
1969). Phosphorylated MSO (figure 2.5) stabilizes the flexible loop structure in the active site of
the enzyme and blocks glutamate entry. Thus, the non-covalently bound form of MSO phosphate
forms a transition state mimic for the tetrahedral adduct of glutamate which is formed during
glutamine biosynthesis. Phosphate ion, ammonia and glutamate in high quantities compete with
MSO for the enzyme binding site (Rowe, Ronzio et al. 1969). Close to eight moles each of MSO
and ADP are required for GS inhibition (Ronzio, Rowe et al. 1969). Also, only the L-S-isomer of
MSO is able to inhibit the enzyme and is phosphorylated by GS (Manning, Moore et al. 1969;
Ronzio, Rowe et al. 1969; Rowe, Ronzio et al. 1969; Meister 1985).
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Figure 2.5. Structure of methionine sulfoximine and methionine sulfoximine phosphate.
Methionine sulfoximine (MSO) is an irreversible inhibitor of glutamine synthetase (GS). GS in
presence of ATP and magnesium binds to MSO and phosphorylates it. Methionine sulfoximine
phosphate binds GS non-covalently to inhibit it.

Methionine Sulfoximine as a therapeutic treatment:
There were two reasons for using MSO as an inhibitor of GS to study ALF. 1) MSO is
the most potent inhibitor of GS. Being a modified amino acid, it can cross the blood brain barrier
– as has been shown by its ability to prevent brain swelling resulting from hyperammonaemia. 2)
Liver GS inhibition by MSO has been studied previously – i.e. MSO inhibition of liver GS is
maximal at 4 hours. GS activity remains low till 72 hours and thereafter increases again (Lamar
1968). This information enabled us to plan our experiments to explore the therapeutic use of
MSO and the effects of GS inhibition on the mouse model of ALF.
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As mentioned earlier, GS is predominantly present in astrocytes, and brain oedema is
prevented in hyperammonaemic rats by MSO treatment (Takahashi, Koehler et al. 1991). MSO’s
therapeutic action has been explored in a mouse model for amyotropic lateral sclerosis
(Ghoddoussi, Galloway et al. 2010). We found that MSO extends the life span of ALS mouse
model (G39A mutant) by 8%. MSO was able to reduce glutamine by 60% and glutamate by 30%
in different parts of mouse brain.
My contribution to this study focused on assaying glutamine synthetase activity from
brain tissue of ALS mice. The same work has been presented below.

Materials and methods:
Animal groups and tissue collection:
Breeding pairs of the SOD1 mouse – B6JL (G93A) – were purchased from Jackson
Laboratories and offspring containing the human SOD1G93A mutation were identified by PCR of
tail DNA, using primers described for this strain by the Jackson Laboratories (jax.org). If the
mice carried the SODG93A mutation they were termed as ALS mice. The mice which did not
express SODG93A mutation were termed as wild type. Separate groups of animals were used to
assess MSO effects on longevity, and GS activity in vitro. All animal experiments were approved
by the Animal Investigation Committee of Wayne State University. Methionine sulfoximine
(MSO), obtained from Sigma Chemical Company (Cat #5379) was dissolved in 0.9% saline and
administered intraperitoneally at a dose of 20mg/kg.
Three experiments were set up to measure the effect of MSO treatment on GS in the
mosue model for ALS.
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Group 1 mice: SODG93A mutant mice were injected with MSO (15 mice) or saline (15
mice), three times every week (Monday, Wednesday, Friday), starting at 50 days of age (±2)
until they were euthanized. Mice were observed daily and were euthanized when either 1) they
lost 20% of their maximum body weight, 2) they were unable to right themselves when put on
their back or side, or 3) if, in the opinion of the supervising veterinarians, the mice were in
distress or unable to obtain adequate food and water. These were used to obtain MSO’s effect on
survival and monitor ALS disease progression. (I assisted in maintenance of the mouse colony,
genotyping and motor function measurement assay.)
Group 2 mice: The effects of MSO treatment in vivo on GS activity in vitro were
analyzed in brain tissue obtained from SODG93A mice and their wild type counterparts. Animals
were treated with either saline or MSO (20 mg/kg, three time a week – Monday, Wednesday, and
Friday – for 3 weeks) starting at 50 days of age (±2 days) and sacrificed at 70 days of age
(±2 days).
Group 3 mice: Lastly, in another set of experiments, animals were treated with MSO at a
dose of 20 mg/kg. MSO was injected starting at 85 ± 2 days of age. At 85 days, ALS symptoms
(such as impaired motor function) appear. Thus, the animals were injected with MSO or saline
once a week post symptomatically, till they met the criteria for euthanization (120 – 130 days).
Glutamine synthetase enzyme activity:
Brains were removed, homogenized, and GS activity determined according to the method
of Meister (Meister 1985). Tissue was immediately homogenized in ice-cold buffer (0.15 M
potassium chloride, 5 mM 2 – mercaptoethanol, and 1 mM EDTA (pH – 7.2)) and centrifuged at
2375 x g for 5 minutes. Tissue supernatant fraction was frozen on dry ice and stored at -80oC.
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Glutamine synthetase was assayed as described by Meister (Meister 1985).

Brain

supernatant (100 µg) was incubated in buffer (0.1 M imidazole – HCl (pH – 7.2), 100 mM Lglutamine, 0.2 mM MnCl2, 62.5 mM hydroxylamine, 10 mM sodium arsenate and 0.4 mM ADP)
at 37oC for 10 minutes. The enzyme reaction with the substrates glutamine and hydroxylamine
was stopped using ferric chloride stop solution (0.37 M FeCl 3, 0.67 M HCl, 0.20 M TCA) and
the colorimetric product formed – γ-glutamyl hydroxamate – was measured at 535 nm. The
absorbance values were converted to activities by comparison to a standard curve of pure
glutamyl hydroxamate (a generous gift from Arthur J. Cooper, Department of Biochemistry and
Molecular Biology, New York Medical College).

Results:
MSO’s effect on GS from brain tissue of group 2 mice:
Each group consisted of 3 animals. GS activity from the brain tissue was 1.1 ± 0.04 in
wild type animals and 0.95 ± 0.05 in ALS animals treated with saline. The activity was
drastically reduced to 0.17 ± 0.03 and 0.18 ± 0.02 in wild type and SOD1 animals respectively,
with MSO treatment. Activity is expressed as µM γ – glutamyl hydroxamate formed/min of
reaction/ mg of protein ± standard error of mean. The results are described in table 2.1.
These results affirmed the potent inhibition of glutamine synthetase by MSO. GS activity
is reduced by more than 85% in both wild type and SOD1 animals with MSO treatment.
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AVERAGE ACTIVITY
GENOTYPE

TREATMENT

SEM
(µM GGH/min/mg of protein)

WT
SALINE

1.10

0.04

0.17

0.03

0.95

0.05

0.18

0.02

(N = 3)
WT
(N = 2)

MSO: 20 mg/ kg body
weight of mice

ALS
SALINE
(N = 3)
ALS
(N = 3)

MSO: 20 mg/ kg body
weight of mice

Table 2.1. Glutamine synthetase activity in brains tissue of 70 day wild type (WT) and ALS
mice with and without MSO treatment is shown above. WT and SOD1 mice have average GS
activity of 1.10 and 0.95 µM γ-glutamyl hydroxamate/ min of reaction/ mg of protein. MSO
inhibits GS and a decrease in average GS activity is observed. GS activity in MSO treated WT
and SOD1 mouse are 0.17 and 0.18 respectively.
MSO’s effect of GS from brain tissue of group 3 mice:
GS activity was 1.2 ± 0.19 in wild type animals (n = 7) and 1.12 ± 0.09 in ALS animals
(n = 16) treated with saline. The activity was reduced by more than 80% to 0.25 ± 0.04 and 0.25
± 0.03 in wild type (n = 6) and ALS (n = 16) animals respectively, with MSO treatment. Activity
is expressed as µM γ – glutamyl hydroxamate formed/min of reaction/ mg of protein ± standard
error of mean. The results are described in table 2.2 below.
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AVERAGE ACTIVITY
GENOTYPE

TREATMENT

SEM
(µM GGH/min/mg of protein)

WT
SALINE

1.19

0.19

0.25

0.04

1.12

0.09

0.25

0.03

(N = 7)
WT

MSO: 20mg/ kg body

(N = 6)

weight of mice

ALS
SALINE
(N = 16)
ALS

MSO: 20mg/ kg body

(N = 16)

weight of mice

Table 2.2. GS activity in brain tissue of 120 day old mice, treated with MSO starting at 85
days in wild type (WT) and ALS mice is shown above. With MSO treatment average GS
activity in WT and SOD1 mice decrease from 1.19 to 0.25 and 1.12 to 0.25 µM GGH/min of
reaction/ mg of protein respectively.

GS activity seems to remain constant in saline treated animals during the course of
disease (comparing group 2 and group 3 mice). Also, long term MSO treatment (one injection /
week, starting at 85 days of age till euthanization) is able to maintain low GS activity.

Discussion:
ALS is an adult onset fatal neurodegenerative disease that results in a progressive loss of
motor neurons (Bruijn 2002). The cause of neurodegeneration in ALS is unknown, but the onset
or progression of ALS is believed to have an excitotoxic component involving glutamate. There
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is no known effective treatment for ALS and patients have very poor prognosis (ALS patients die
within a few years after disease onset.)
We wanted to determine the effect of limiting glutamine formation in brain. For the same,
we treated animals with glutamine synthetase inhibitor MSO, which would affect the glutamine –
glutamate cycle in brain. We found that chronic treatment of SOD1G93A transgenic mice with
MSO over an extended period of time (at least 10–11 weeks) significantly (p = 0.008) increased
their life span by 8%, as compared to saline-treated animals Survival increased from
138 ± 3 days to 149 ± 4 (SEM) days for SOD1G93A transgenic mice (data not shown in this
chapter). The survival analysis for MSO-treated and saline-treated groups (n = 15 each) show the
survival range for saline-treated animals was 119 to 157 days, and the survival range for MSOtreated animals was 128 to 167 days. Corresponding to an increase in survival we saw an 80 85% decrease in brain GS activity in brain tissue of the animals. Work done by our collaborators
Dr. Farhad Ghoddoussi and Dr. Matthew P. Galloway found that the decrease in GS activity
could be responsible for amino acid fluctuations that were seen in brain sections of the animals.
Proton magnetic resonance spectroscopy, with magic angle spinning of intact samples of brain
tissue, showed that MSO treatment reduced brain levels of glutamine by 60% and of glutamate
by 30% in both the motor cortex and the anterior striatum (full text of the paper explains the
various changes).
For the purpose of my thesis, these results were indicative of potent GS inhibition by
MSO. Glutamine is required by immune cells for cellular proliferation, differentiation and
cytokine production (Li, Yin et al. 2007), and so its modulation would have an impact on
immune and inflammatory process.
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Hence, to investigate the role of glutamine and glutamine synthetase in
inflammation and encephalopathy we proposed to study the effects of MSO in acute liver
failure (ALF) using the LPS/D-GalN liver injury model.
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CHAPTER 3
A Glutamine Synthetase inhibitor increases survival and decreases cytokine response in a
mouse model of Acute Liver Failure

The work presented in this chapter was first published as and in:
A glutamine synthetase inhibitor increases survival and decreases cytokine response in a
mouse model of acute liver failure
Publication history: Liver international, Volume 31, Issue 8, September 2011, Pages 1209 –
1221
Authors: Amruta A. Jambekar1, Elena Palma2, Luca Nicolosi2, Andrea Rasola2, Valeria
Petronilli2, Frederica Chiara2,3, Paolo Bernardi2, Richard Needleman1 and William S.A.
Brusilow1
1

Department of Biochemistry and Molecular Biology, Wayne State University School of

Medicine, 540 E. Canfield Ave., Detroit, MI, USA
2

Department of Biomedical Sciences, University of Padova, Padova, Italy

3

Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy

Introduction
As mentioned earlier, Acute Liver Failure (ALF) is defined as rapid deterioration of liver
function in the absence of pre-existing liver disease and is characterized by blood coagulation,
multi-organ failure, and altered mental status. ALF can be triggered by diverse agents such as
drugs (acetaminophen, thioacetamide, and α-amanitin) and viruses (primarily hepatitis viruses A,
B, and E). A critical feature of ALF is the mounting of a massive immune response, with
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recruitment of cellular effectors and uncontrolled cytokine release, a so-called cytokine storm,
which destroys healthy cells and organs, leading to death. There is currently no effective therapy
against ALF, a condition that kills between one and six people per million every year (Bernal,
Auzinger et al. 2010).
ALF is relatively rare, but it is one of many conditions resulting from a unrestrained
cytokine release, and a pathological cytokine release is also believed to be involved in many
other diseases that occur much more frequently, including rheumatoid arthritis (Chen and
Goeddel 2002), Parkinson’s disease (Park, Yule et al. 2008), acute pancreatitis (Makhija and
Kingsnorth 2002), and complications from flu infection (e.g. sudden acute respiratory syndrome
(SARS)(Wang, Le et al. 2010).
A well-established mouse model of ALF consists of injecting animals with a combination
of low doses of E. Coli lipopolysaccharides (LPS, which activates the innate immune response)
and D-Galactosamine (D-GalN, which specifically sensitizes the liver towards the cytotoxic
effects of LPS through a transcriptional block (Decker and Keppler 1974; Galanos, Freudenberg
et al. 1979; Leist, Gantner et al. 1998). This induces a systemic response which is predominantly
directed towards liver. As the liver fails, the resultant hyperammonemia produces brain edema
similar to the brain swelling seen in hepatic encephalopathy of humans that results from liver
disease(Groflin and Tholen 1978; Watanabe, Higashi et al. 1979) .
Brain swelling is prevented in hyperammonemic rats by treatment with methionine
sulfoximine (MSO) (Takahashi, Koehler et al. 1991; Tanigami, Rebel et al. 2005). MSO is a
modified amino acid that acts as a very strong mechanism-based inhibitor of glutamine
synthetase, the ATP-dependent enzyme that converts glutamate and NH3 into glutamine – a
central reaction in cellular nitrogen metabolism (Manning, Moore et al. 1969; Ronzio, Rowe et
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al. 1969; Griffith, Anderson et al. 1979). MSO displays multiple additional biological activities;
increases survival in a mouse model of amyotrophic lateral sclerosis (Ghoddoussi, Galloway et
al. 2010), it inhibits the first step in glutathione synthesis, γ-glutamyl cysteine synthetase
(Griffith, Anderson et al. 1979), and it lowers S-adenosyl methionine levels by an unknown
mechanism (Schatz and Sellinger 1975).
We have been exploring the therapeutic use of MSO in the LPS/D-GalN mouse model of
ALF, by studying if MSO affects the early events that lead to liver failure. We have found that
pretreatment with MSO greatly increases the survival of mice challenged with LPS/D-GalN. The
mechanism of action of MSO in this system appears to involve a reduction in the early cytokine
response of macrophages, indicating that glutamine synthetase activity is required for cytokine
synthesis elicited by LPS/D-GalN in inflammatory cells.

Materials and Methods
Animals:
6-8 week old CD1 mice were obtained from Charles River. Animals were housed in
Wayne State University. Food was withdrawn the night before the day of the experiment. All
experiments were approved by the Animal Investigation Committee of Wayne State University.
The universities complies with the criteria outlined in the "Guide for the Care and Use of
Laboratory Animals" prepared by the National Academy of Sciences and published by the
National Institutes of Health (NIH publication 86-23 revised 1985).
Survival and Analysis:
Animals were divided into two groups. Group one animals consisted of both male and
female mice injected with LPS and D-GalN to induce hepatic failure. Survival was monitored
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post LPS/D-GalN administration and the time of injection was considered to be zero hour (t=0).
Group two animals consisted of mice injected with MSO three hours prior to LPS and D-GalN
administration. A mixture of LPS (20 µg/kg body weight, sigma – LPS from E. Coli 0111:B4
Sigma #L2630) and D-GalN (800 mg/kg body weight, Sigma cat #G1639) was prepared in saline
and administered intraperitoneally (IP). MSO (50 mg/kg body weight, Sigma cat #M5379) was
also prepared in saline and administered IP. For analysis of the effect of MSO treatment on the
cell death pathway activated by the Fas ligand, mice were pre-treated with MSO as described
above, and at time zero were injected with Jo2 antibody (200 µg/kg).
Animals were monitored continuously post LPS/D-GalN or Jo2 administration. Six to ten
hours after treatment with LPS/D-GalN animals became very sick, and they were euthanized if
their distress increased to the extent that they had difficulty moving, or if they were unresponsive
to prodding. The time of death was recorded as hours after LPS/D-GalN injection. Fisher’s exact
test was used to determine two-tailed p values for the statistical between the treated and
untreated groups.
Immunoblots of cleaved caspase-3 and phospho-STAT proteins:
Liver homogenates were prepared from male mice five hours after IP administration of
LPS/D-GalN. The proteins in liver homogenates were separated on a 10% SDS-PAGE slab mini
gels, electro-blotted onto nitrocellulose membranes (Amersham Biosciences Little Chalfont, UK
– HybondTM-ECLTM) and the membranes were sequentially immunoblotted with antibodies
against cleaved caspase-3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH – Chemicon,
Milano, Italy) was used as a loading control). Other antibodies used in these studies included
Phospho-STAT antibodies (cell Signaling cat # 9914), including phospho-STAT1 (Tyr701),
phospho-STAT2 (Tyr690), phospho-STAT3 (Tyr705), phospho-STAT3 (Ser727), phospho-
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STAT5 (Tyr694), and phospho-STAT6 (Tyr641). Anti-rabbit IgG, HRP-linked secondary
antibody was used and the blots were developed either using the Immun-Star WesternC Kit
(BIO-RAD cat # 170-5070) on a BIO-RAD imager.
Caspase-3 blots of our Italian collaborators were used in the paper. However, the
experiment was repeated and the result presented in this chapter was obtained by me.
Isolation of peritoneal macrophages:
Peritoneal macrophages were isolated from the abdomens of CD-1 mice, and 2x104 cells
were added to each well of a 6-well cell culture plate. The cells were incubated in RPMI – 1640
(with 2.05 mM glutamine) with 5% fetal calf serum and 1% penicillin/streptomycin (all solutions
were from Hyclone) for 4 hours. The medium was then changed to remove any non-adherent
cells, and the cells were again incubated in a 37 oC - 5% CO2 incubator for 16 hours. In each
plate, one well was a negative control (no treatment), one well was a MSO control (9 mM) and
one well was a LPS control (1 µg/ml LPS). The other three wells were treated with 9 mM MSO
and 1 µg/ml LPS. One well was treated with MSO for 3 hours, and LPS was then added. In
another well, LPS and MSO were added at the same time. Time of LPS addition was considered
time zero. Four hours after LPS addition the cell culture medium was collected and 50 µl of the
medium was mixed with 50 µl of blocking buffer and used for the TNF-α ELISA assay.
Animal groups for tissue and plasma collection:
Tissue and plasma were collected from male mice, which were divided into two groups.
One group was injected with saline three hours prior to LPS/D-GalN injections. The second
group was given MSO three hours prior to being injected with LPS/D-GalN. Control mice (t=0)
were treated with MSO or saline for 3 hours and then euthanized (not exposed to LPS/D-GalN).
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After LPS/D-GalN injection at time zero, tissue and plasma samples were collected at one-hour
time intervals from 1 to 5 hours.
Blood collection and plasma preparation:
For experiments analyzing plasma cytokines, the male mice from the groups described
above were anesthetized using Avertin (solution of 15.5 ml of tert-amyl alcohol –Sigma #240486
and 25 gm of 2-2-2 tribromoethanol – Sigma #T48402) and blood was collected by cardiac
puncture. Plasma was obtained by transferring blood to plasma separator tubes containing
lithium heparin (BD Microtainer tubes). Plasma samples were immediately frozen on dry ice and
stored at -80oC.
Enzyme activity assay:
To analyze enzyme activities liver homogenates were prepared from liver tissue excised
and immediately homogenized in ice-cold buffer consisting of 250 mM sucrose, 10 mM Tris and
0.1 mM EGTA with protease inhibitor cocktail (sigma #P8340). The homogenized tissue was
centrifuged at 2375 x g for 5 minutes. The tissue supernatant fraction was frozen on dry ice and
stored at -80oC.
Glutamine synthetase was assayed as described by Meister (Meister 1985).

Liver

supernatant (100 µg) was incubated in buffer (0.1 M imidazole, 100 mM L-glutamine, 0.2 mM
MnCl2, 62.5 mM hydroxylamine, 10 mM sodium arsenate and 0.4 mM ADP) at 37oC for 15 min.
The reaction with the substrates glutamine and hydroxylamine was stopped using ferric chloride
stop solution (0.37 M FeCl3, 0.67 M HCl, 0.20 M TCA) and the colorimetric product formed – γglutamyl hydroxamate – was measured at 535 nm. The absorbance values were converted to
activities by comparison to a standard curve of pure glutamyl hydroxamate (a generous gift from
Arthur J. Cooper, Department of Biochemistry and Molecular Biology, New York Medical
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College). Graphpad analysis software was used to obtain two-tailed p values using an unpaired t
test.
Cytokine Blots:
Mouse cytokine array kits (Proteome Profiler Arrays – cat # ARY006) were obtained
from R&D Systems and used according to the manufacturer’s guidelines. Each array, which
consisted of a nitrocellulose membrane spotted with 40 different mouse cytokines, was tested
with two hundred microliters of plasma from one animal. Each condition was duplicated – two
mice for each group. Control blots were from plasma collected from two untreated mice (not
injected with LPS/D-GalN and/or MSO). For untreated and MSO-treated groups, plasma was
collected at either 1 hour or 3 hours after LPS/D-GalN administration. The blots were developed
using the Immun-Star WesternC Kit (BIO-RAD cat # 170-5070) on a BIO-RAD imager. The
corresponding Quantity One software of the BIO-RAD imager was used to quantify the signal
obtained on the blots.
ELISA assays:
TNF-α, IFN-γ, and IL-6 ELISA kits were obtained from eBioscience, and experiments
were performed using the manufacturer’s guidelines for 96-well plate experiments. One hundred
microliters of plasma was used per well. The TNF-α ELISA assay had a sensitivity of 8-1000
pg/ml: the IFN-γ ELISA had a sensitivity of 0.75 – 100 pg/ml. The IL-6 ELISA assay had a
sensitivity of 0-500 pg/ml, and the combination of ELISA sensitivity and the amounts of IL6 in
plasma required us to reduce the amount of plasma tested to 5 µl.
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Results
MSO prevents LPS/DGalN induced ALF lethality in mice:
Figure 3.1 shows survival curves for CD1 mice treated with LPS/D-GalN to induce liver
failure. Mice were injected with MSO three hours prior to LPS/D-GalN treatment. Without
MSO pre-treatment, LPS/D-GalN administration resulted in death 6 - 10 hours after
administration. MSO pretreatment increased male survival from 19% to 71% (Figure 3.1A)
n=21; p<0.002 . MSO pre-treatment increased female survival from 27% to 81% (Figure 3.1B)
n=14; p<0.005. MSO therefore substantially increases survival in both male and female mice
with LPS/D-GalN induced ALF.

Figure 3.1. Survival of male and female CD1 mice pretreated with either MSO (open circles)
(50 mg/kg IP) or saline (open diamonds) three hours prior to injection with LPS and DGalactosamine (D-GalN) at time zero to induce liver failure. Time of death was recorded as
hours after LPS/D-GalN injection (X axis), and percent remaining animals was plotted on the Y
axis. For males (left), 4 out of 21 mice injected with LPS/D-GalN survived. Survival increased
to 15 mice (out of 21) when animals were injected with MSO. Two tailed p values for these two
groups < 0.002. For females (right), 3 out of 14 mice injected with LPS/D-GalN survived.
Survival increased to 11 mice (out of14) when animals were pretreated with MSO. Two tailed p
values for these two groups < 0.005.
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MSO treatment reduces activity of glutamine synthetase:
MSO is a well-characterized inhibitor of glutamine synthetase. We assayed glutamine
synthetase activity in liver extracts from LPS/D-GalN treated animals. Figure 3.2 shows that at
all time points, MSO pre-treatment reduced glutamine synthetase activity to less than 10% of
that found in animals pre-treated with saline, supporting the conclusion that inhibition of
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Figure 3.2. Glutamine synthetase activities measured in liver extracts from mice treated
with LPS and D-GalN three hours after IP injection of either saline (black bars) or MSO (grey
bars). Each time point represents the average glutamine synthetase activity in liver extracts from
15 animals.

MSO inhibits the massive cytokine response seen in LPS/D-GalN treatment:
One of the earliest effects of LPS/D-GalN administration is to trigger the release of proinflammatory cytokines(Leist, Gantner et al. 1998). We exploited a mouse cytokine array to
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determine how MSO treatment affected plasma levels of 40 different cytokines following
treatment of mice with LPS/D-GalN in order to draw a comprehensive picture of how MSO
might be affecting the early immune response. We used these arrays to visualize the cytokine
response in plasma collected one hour or three hours after LPS/D-GalN administration. Figure
3.3 shows the cytokines seen in plasma drawn one and three hours after LPS/D-GalN
administration with or without MSO treatment. Each blot represents the plasma from a single
animal. For Figure 3.3A (i), the two control blots, were on plasma isolated from negative
controls (overnight-starved animals not treated with MSO or LPS/D-GalN). We analyzed blots
of plasma taken from two animals killed three hours after LPS/D-GalN administration, shown in
Figure 3.3A (ii). Figure 3.3A (iii) shows the two blots of plasma from animals pretreated with
MSO three hours prior to LPS/D-GalN injection. For the locations of each of the 40 cytokines
detectable in these blots, see http://www.rndsystems.com/pdf/ary006.pdf
The results showed that, as expected, secretion of many of these cytokines is dramatically
increased during ALF progression. Three hours after disease induction, 22 of the 40 cytokines
were found to be elevated and 20 of these were reduced by MSO pretreatment. The results for
all 40 cytokines are summarized in Figure 3.4A and figure 3.4B, and the major differences are
described in the following paragraphs.
Cytokines C5a, sICAM-1, KC, M-CSF, and TIMP-1 were all detected on the control
blots. In the one-hour samples from LPS/D-GalN-treated mice (figure 3.3B (i)), only IL-6, KC,
M-CSF, JE, MIP-2, TNF-α and TIMP-1 were elevated, and only IL-6 and TNF-a were reduced –
both by >50% - in plasma from MSO-pretreated animals (figure 3.3B (ii)). The signal intensity
calculations from one hour blot samples are shown in figure 3.4C. Three hours after LPS/DGalN treatment, both LPS/D-GalN treated animals and MSO-pretreated LPS/D-GalN treated

67

animals showed a 10-20% reduction in C5a and sICAM. M-CSF values were the same for all
three groups. KC and TIMP-1 signals were increased by more than 50% in LPS/D-GalN treated
mice. KC values for MSO pre-treated values were same as in LPS/D-GalN animals; however,
TIMP-1 values were reduced to approximately control values.
Induction of IFN-γ, IL-1ra, IL-6, IL-16, and IL-23 by LPS/D-GalN was abolished by
MSO, whereas IL-1a level was reduced by more than 50%. Neutrophil-produced cytokines such
as IP-10, I-TAC and MIG were all detected in plasma from LPS/D-GalN treated mice. IP-10 was
reduced by more than 50% with MSO pretreatment and MIG and I-TAC were not detected.
Macrophage-produced cytokines such as MIP-1a and MIP-1b, and chemokines such as JE and
RANTES, which were elevated with LPS/D-GalN treatment, were either reduced or not detected
with MSO pretreatment. The two exceptions were MCP-5 (monocyte chemotactic protein) and
MIP-2 (macrophage inflammatory protein -2 gamma), both of which were increased in plasma
from MSO-treated animals. Most importantly, TNF-α induction by LPS/D-GalN was abrogated
by MSO pretreatment.
Lastly, figure 3.3C (i) shows blot from one female LPS/ D-GalN animal and figure 3.3C
(ii) was obtained from plasma of one female mouse pre – treated with MSO. Since, the cytokine
profile from female mice was similar to those from male mice; densitometry analysis from the
blot was not performed and the experiment was not repeated with more animals.
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Figure 3.3. Nitrocellulose membrane-based cytokine arrays. Cytokine arrays were obtained
from R&D Systems. Each membrane has 40 different mouse cytokines spotted in duplicate.
The cytokines were identified using the column and lane number of each spot corresponding to
the manufacturers table. Each membrane contained three positive and one negative control, each
spotted in duplicate. Each blot represents the plasma cytokine profile from a single mouse.
Panel A (i) shows cytokines in plasma from a control mouse (not treated with either MSO or
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LPS-DGalN). 3.3. A (ii) show cytokines from plasma of animal treated with LPS/D-GalN 3
hours post disease induction and 3.3. A (iii) shows plasma from MSO pretreated animal. Panel
B shows cytokines in plasma from a mice treated with LPS/D-GalN (3.3. B (i) and MSO +
LPS/D-GalN (3.3. B (ii) )for one hour. Panel C shows cytokines in plasma from female mice
treated with LPS/D-GalN (3.3.C (i)) and pretreated with MSO three hours before being treated
with LPS/D-GalN (3.3. C (ii)) for three hours. For the locations of each of the 40 cytokines
detectable in these blots, see http://www.rndsystems.com/pdf/ary006.pdf
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Figure 3.4. Changes in cytokines calculated from cytokine array blots. Each treatment group
had two animals in it and the values for the 40 different cytokines were averaged for each group
and represented as pixel densities, normalized to the average pixel densities of the positive
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controls (PC1), and plotted on this bar graph. Figure A and B show all the cytokines present in
control, LPS/D-GalN and MSO – LPS/D-GalN treated animals. The cytokines not detected on
the blots are not shown. Open bars represent the cytokine values for untreated negative control
mice. Black bars represent the cytokine values for mice treated with LPS/D-GalN. Grey bars
represent the cytokine values for mice pretreated with MSO three hours before being injected
with LPS/D-GalN. The error bars represent the maximum pixel density for the cytokine. A and
B) Shows the signal intensity calculation from cytokine blots of three hour diseased animals –
figure 3.3 A i, ii, and iii. C) Shows signal intensity calculation from cytokine blots of one hour
diseased animals – figure 3.3. B i, and ii.

ELISA studies on plasma cytokines:
TNF-α and IFN-γ are secreted by different cells as part of the response to LPS
administration, and we see both in the cytokine arrays described above. TNF-α and IFN-γ
activate separate apoptotic pathways. TNF-α activates cell death via the JNK pathway (Schwabe
and Brenner 2006) and IFN-γ activates apoptosis via the Jak-STAT1 pathway (Horvath 2004).
To identify the effect of MSO on secretion of these two cytotoxic cytokines, we followed up the
cytokine array studies with ELISA analysis of plasma levels of TNF-α and IFN-γ. Figures 6A
and 6B show ELISA assays carried out on plasma taken from individual mice killed either at t=0
(control animals – injected with MSO or saline for 3 hours, but not exposed to LPS/D-GalN) and
at 1, 2, 3, 4, or 5 hours after LPS/D-GalN treatment. These are the same mice for which
glutamine synthetase activities in liver extracts are shown in Figure 3.2.
Figure 3.5A shows that TNF-α was not detectable in plasma taken from t=0, control
mice injected three hours previously with either MSO (n=7) or saline (n=7). For saline pretreated
and LPS/D-GalN-treated animals, TNF-α levels peaked at one hour (mean: 590 ± 91 SEM
pg/ml) then dropped at later times. In contrast, MSO-pre-treated animals exhibit low TNF-
levels throughout the time course of experiment, never reaching 200 pg/ml (peak 1 hour time

71

point mean: 112 ± 35 SEM pg/ml). The p value for the difference between the saline-treated and
the MSO-treated groups of mice at 1 hour is < 0.001.
Another important cytokine whose expression is elicited by LPS is IFN-γ, which could
contribute to apoptosis regulation via activation of the JAK/STAT pathway (Horvath 2004).
Figure 3.5B shows that LPS/D-GalN-treatment increases IFN-γ cytokine levels from 0.84±0.25
pg/ml at one hour to 41±11 pg/ml at 4 hours, and that MSO markedly inhibits this increase
(0.19±0.05 pg/ml at 1 hour; 5.0±3.0 pg/ml at 4 hours). The p value for differences between the
LPS/D-GalN and MSO treated groups of mice at 4 hour is 0.01.
We also conducted ELISA assays to test the effect of MSO pretreatment on IL-6, another
acute phase protein involved in orchestrating the early phases of the inflammatory response
(Streetz, Wustefeld et al. 2001).IL-6 is secreted by macrophages in liver and along with TNF-α is
a critical early mediator of immune signaling during disease progression. Low levels of IL-6 are
hepatoprotective, and the resultant low levels of STAT3 activation are also hepatoprotective. As
described above, IL-6, like TNF-α, is seen in the cytokine blots of both the one-hour and threehour plasma samples from LPS/D-GalN treated mice. Figure 3.5C shows that LPS/D-GalN
treatment increases IL-6 from 166±41 pg/ml (mean ± SEM) at one hour to 401±14 pg/ml (mean
± SEM) at two hours. Thereafter it decreases gradually till 5 hours. The plasma from MSO pretreated mice show low levels of IL-6, with a peak of (mean) 325 ± 27 SEM pg/ml at 3 hours. The
p value for the difference between the saline-treated and the MSO-treated groups of mice at 1
hour is < 0.001.
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Figure 3.5. ELISA quantitation of cytokine levels in plasma from LPS/D-GalN treated
mice. The time zero values show the levels of each cytokine in negative control mice, not
treated with LPS/D-GalN but injected with either saline (n=7) or MSO (n=7) three hours prior to
be killed. Each of the hour time points shows cytokine levels in 7 or 8 mice killed at that time
point after LPS/D-GalN treatment. For each cytokine, open red circles represent cytokine levels
in plasma isolated from mice pretreated with saline, and open blue diamond’s represent cytokine
levels in plasma isolated from mice pretreated with MSO prior to LPS/D-GalN treatment. A)
TNF-α levels. B) IFN-γ levels. C) IL-6 levels.
MSO inhibits STAT1 activation and caspase – 3 cleavage:
The effects of IFN-γ as well as other IFNs, are mediated by its activation of the tyrosine
kinases Jak1 and Jak2, which phosphorylate and activate the transcription factors of the STAT
family (Levy and Darnell 2002). As this is the primary pathway for the activation of IFN-γ.
responsive genes we wished to determine if the reduction in IFN-γ seen with MSO was sufficient
to affect this pathway. As can be seen in figure 3.6, LPS/D-GalN treatment leads to a large
increase in STAT1 activation and this increase is eliminated in the presence of MSO. We also
tested the effects of MSO treatment on activation of STAT2, 3, 5, and 6. None showed effects as
dramatic as those seen with STAT1, but phosphorylated STAT3 is decreased by MSO-treatment
in both LPS/D-GalN treated and untreated mice.
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Figure 3.6. Immunoblots of liver tissue homogenates from LPS/D-GalN treated mice
probed with anti phospho-STAT’s. The top two lines show treatments, either LPS/D-GalN,
MSO, neither, or both. The blot shows that LPS/D-GalN treatment phosphorylates and activates
STAT1, but not if mice are pretreated with MSO. Glyceraldehyde phosphate dehydrogenase
(GAPDH) is shown as a loading control. Phosphorylated STAT2, 5 and 6 was not detected in
any treatment group. STAT3 phosphorylated at S727 was present in LPS/D-GalN treated animal
and absent with MSO treatment.

Caspase 3 is a key apoptotic effector, both in intrinsic and in extrinsic apoptotic pathways, and it
is activated downstream to engagement of TNF or Fas receptors(Taylor, Cullen et al. 2008). We
therefore measured caspase-3 activation as a hallmark of apoptosis induction in mouse liver
extracts. Figure 3.7 show that, animal exposure to LPS/D-GalN for 5 hours elicits a marked
caspase-3 activation, which is completely prevented by MSO pretreatment. This suggests that
MSO acts either downstream to TNF-α binding to its cognate receptor, blunting some
intracellular steps of apoptosis signaling; or upstream to TNF-R engagement, e.g. by inhibiting
ligand production or delivery.
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Figure 3.7. Effect of MSO treatment on caspase-3 activation. Western immunoblots of liver
extracts were hybridized with anti-cleaved, i.e. activated caspase-3. First lane is control –
untreated with LPS/D-GalN and MSO. Second lane is LPS/D-GalN sample and third lane is
MSO pretreated LPS/D-GalN tissue. MSO treatment reduces formation of active caspase – 3.
Three different lanes are shown. Blots were probed with anti-GAPDH as a loading control.
Effects of MSO on in vitro production of TNF-α by peritoneal macrophages
Taken together, our data demonstrate that MSO exerts its protective function prior to
apoptosis induction in hepatocytes, as it down-modulates cytokine induction following LPS
exposure. Macrophages coordinate the early phases of LPS-induced inflammatory response,
through the synthesis of TNF-α and other cytokines. We conducted in vitro experiments to
directly test if MSO inhibits TNF-α production on LPS-stimulated macrophages obtained from
mouse peritoneum. Macrophages were triggered with LPS with or without MSO added either
three hours before, or at the same time of LPS. Four hours after LPS addition, TNF-α in the
culture supernatant was quantitated by ELISA.

In six experiments, we found that MSO
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treatment three hours before LPS addition resulted in an average decrease in TNF-α production
of 26% with a range of 14% to 55%. MSO treatment at the same time as LPS addition resulted
in an average decrease in TNF-α production of 18% with a range of 8% to 37%. Trypan blue
testing confirmed that there was no effect of MSO on cell viability over the time course of these
experiments. This experiment verified that MSO can act directly on macrophages to inhibit
cytokine production, despite the presence of 2 mM glutamine in the culture medium. These
results with peritoneal macrophages show that MSO does decrease TNF in the presence of
external glutamine, but since Kupffer cells are likely to have the major role in TNF-α production
in these experiments, and since the local concentration of glutamine will be different than the
plasma levels for these cells, additional experiments will be needed to see if the inhibition of GS
is sufficient to account for the diminution of the immune response. The significance of MSO
acting even in the presence of external glutamine is discussed below.

Discussion
Methionine sulfoximine is a well characterized inhibitor of glutamine synthetase and
gamma-glutamyl cysteine synthetase (Griffith and Meister 1978). It is a mechanism-based (i.e.
“suicide”) inhibitor for both enzymes, whose mode of action involves binding to the active site
and being phosphorylated by ATP. This reaction produces methionine sulfoximine phosphate,
which binds very tightly to the active site and inactivates the enzyme. In rats, MSO-treatment
and inhibition of glutamine synthetase has been shown to prevent brain swelling caused by
hyperammonemia and MSO has been suggested as a possible treatment for hepatic
encephalopathy (Takahashi, Koehler et al. 1991; Brusilow 2002; Tanigami, Rebel et al. 2005).
Because of its effectiveness in those studies, we had initially included MSO treatment as an
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adjunct therapy to other drugs targeting the mitochondrial permeability transition, a
mitochondrial channel whose prolonged opening irreversibly commits cells to death, as PTP
dysregulation is implicated in ALF and other liver diseases (Rasola and Bernardi 2007). The
unexpected effectiveness of MSO by itself led to these studies on MSO alone.
Treatment of mice with MSO alone three hours prior to inducing liver failure with LPS
and D-GalN significantly increased survival. Subsequent analyses showed that MSO treatment
prevented caspase-3 activation, indicating that this drug was affecting a stage upstream to cell
death in the uncontrolled response which is primarily directed against the liver during ALF
(Strasser, O'Connor et al. 2000; Leist and Jäättelä 2001; Luan, Zhou et al. 2007). Immunoblot
analysis showed that MSO pretreatment reduced the production of several pro-inflammatory
cytokines, and more sensitive ELISA studies showed that MSO suppressed the production of
TNF-α and IFN-γ. TNF-α is an important acute phase protein whose production by macrophages
and binding to the TNF-α receptor on hepatocytes activates a network of signal transduction
pathways that regulate gene expression and cell death. When transcription is blocked, e.g. with
D-GalN, pro-apoptotic pathways, including aggregation of a death-inducing signaling complex
and activation of the stress kinase JNK, prevail and lead to a rapid cell dismantling (Schwabe
and Brenner 2006; Wullaert, Heyninck et al. 2006). IFN-γ is produced in the liver by natural
killer (NK) and NK T cells and is involved in the immune response against viral and bacterial
infections by stimulating macrophages to produce more cytokines(Saha, Jyothi Prasanna et al.
2010). Moreover, IFN-γ is independently capable of initiating cell death by inducing the JakSTAT pathway (Levy and Darnell 2002), and we see STAT1 activation in the livers of LPS/DGalN treated mice. MSO treatment affects both the TNF-α and IFN-γ - dependent pathways, but
the suppressive effect of MSO treatment on TNF-α and IFN-γ production also involves a larger
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suppression of cellular immunity, since MSO treatment affects the levels of other macrophage
secreted cytokines such as MIG, MIP-1a, MIP-1b, and MCF in plasma drawn 3 hours after
disease induction. Most of these cytokines were either absent or reduced by more than 50% in
the plasma from MSO pre-treated mice.
The simplest explanation for the ability of MSO to alter the immune response initiated by
LPS/D-GalN is that changes in glutamine concentration, either in the plasma or in immune cells,
affect the activation of immune cells, most likely peritoneal macrophages or Kupffer cells, since
these cells are the earliest producers of TNF-α after an IP administration of LPS. It is well
established that glutamine levels influence macrophage function and cytokine release in tissue
culture, and long-term dietary changes can modify

immune function in living animals

(Newsholme 2001; Li, Yin et al. 2007; Roth 2007). The action of MSO on glutamine synthetase
may be lowering plasma glutamine and thereby changing the global anabolic response to
infection. In vitro, lowered glutamine leads to decreased proliferation in mitogen-stimulated
lymphocytes and impairs the differentiation of plasma cells (Crawford and Cohen 1985; Szondy
and Newsholme 1989).

The reduction in glutamine seen after severe burns may also be

responsible for the impaired immune response seen in this and other stress conditions (Kew,
Wells et al. 1999). Again in vitro, a detailed study of the effect of glutamine concentrations on T
cell differentiation divided the response into an early and glutamine-independent phase and a
latter glutamine dependent phase (Hörig, Spagnoli et al. 1993). Finally, dietary glutamine
enhances cytokine production in macrophages and increases T cell responsiveness (Kew, Wells
et al. 1999; Rogero, Tirapegui et al. 2008).
It has been shown that macrophage depletion improves survival in mice challenged with
LPS/D-GalN (Emoto, Emoto et al. 2003), and that transfer of macrophages from wild type mice
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in TL4R-mutant mice is sufficient to confer susceptibility to LPS/D-GalN – induced lethality
(Freudenberg, Keppler et al. 1986). The relative importance of peritoneal and Kupffer cells in
the lethality caused by LPS/D-GalN is not known, but the conventional view is that, given the
large mass of Kupffer cells and their close proximity to hepatocytes, their secretion of TNF-α
and other cytokines is the proximate cause of death (Luster, Germolec et al. 1994; Ide,
Kuwamura et al. 2005; Tacke, Luedde et al. 2009). Since inhibiting glutamine synthetase can
affect cell death, MSO might be inhibiting Kupffer cell response by either decreasing the
external concentration of plasma glutamine in the vicinity of Kupffer cells, or by directly
inhibiting cellular glutamine synthetase, as we have shown here for peritoneal macrophages
treated with MSO in vitro. The fact that treatment of isolated peritoneal macrophages with 9mM
MSO in the presence of 2mM glutamine significantly reduces TNF-α indicates that even in the
presence of external glutamine, peritoneal macrophage glutamine synthetase is still required for
maximal TNF-α synthesis and/or secretion. Since Kupffer cells are likely to have the major role
in the production of TNF-α in our experiments, additional and more complex experiments will be
needed to determine if the inhibition of glutamine synthetase in these cells is sufficient to
account for the striking diminution of the immune response which we observe.
However, studies of the in vitro effects of glutamine on isolated systems of immune cells
are obviously inadequate for understanding the complex events occurring with LPS/D-GalN
stimulation. We have demonstrated that an IP injection of 50 mg/kg MSO lowers plasma
glutamine concentrations by about 50 %. Under long term MSO treatment, plasma glutamine
levels return to normal even though glutamine synthetase in the liver remains inhibited by 90%,
presumably due to the large amounts of glutamine present in the standard mouse diet. In any
case, plasma glutamine levels might be of minimal importance in the context of macrophage
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activation in the liver, where the local production of glutamine by glutamine synthetase may
influence the external concentration seen by Kupffer cells. As blood in the liver flows from the
portal to the venous side, glutamine concentrations change. The periportal cells actively transport
glutamine, concentrating it by 10 fold (Häussinger, Lang et al. 1990; Labow and Souba 2000).
This removal of glutamine is central to liver function since it is converted by liver glutaminase
into urea and glutamate, controlling blood ammonia levels through its incorporation into urea.
Both glutamate and urea are transported back into the periportal blood. As the glutamateenriched and glutamine-depleted blood reaches the perivenous side of the liver, glutamate is
transported into the perivenous cells and used by glutamine synthetase to make glutamine, which
is then available to Kupffer cells associated with the perivenous hepatocytes. Perivenous
hepatocytes, while constituting only 5% of the hepatoocyte population are the only liver cells
containing glutamine synthetase (Gebhardt and Mecke 1983; Häussinger, Stoll et al. 1989).
There are two populations of Kupffer cells as distinguished by morphology, function, and
location. The Kupffer cells at the periportal side are more active in phagocytosis while those at
the perivenous side respond much more strongly to LPS (Sleyster and Knook 1982;
Hoedemakers, Morselt et al. 1995; Armbrust and Ramadori 1996; Bykov, Ylipaasto et al. 2004).
As noted above, it is clear that glutamine is required for the activation of immune cells. Our
results suggest that the immunologically reactive Kupffer macrophages may be dependent upon
the glutamine synthesized specifically by perivenous hepatocytes. The inhibition of glutamine
synthetase in this population by MSO could reduce the response to LPS/D-GalN, independent of
any changes in plasma levels of glutamine.
An additional mechanism independent of plasma glutamine levels may also be involved.
As shown in this report, MSO is also able to reduce TNF-α secretion in isolated peritoneal
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macrophages even in the presence of 2mM glutamine, implying that the macrophage glutamine
synthetase is directly involved in the synthesis and/or secretion of TNF-α.
Finally, inhibition of glutamine synthetase by MSO may reduce internal glutamine in
immune cells and thereby interfere with energy generation or another critical biochemical
processes required for activation. For example, mTOR activation requires an internal pool of
glutamine and the critical size of this pool may be altered by the inhibition of glutamine
synthetase by MSO (Nicklin, Bergman et al. 2009). Liver tumor cells often have high levels of
glutamine synthetase and presumably internal glutamine, priming them for proliferation (Apte,
Singh et al. 2009; Nicklin, Bergman et al. 2009). In addition, the synthesis of glutamine
synthetase is under the control of the Wnt/β-catenin signaling pathway with β-catenin required
for three enzymes involved in glutamine metabolism, including glutamine synthetase (Sekine,
Lan et al. 2006; Apte, Singh et al. 2009), again suggesting that glutamine plays a central role in
hepatocyte metabolism.
In conclusion, MSO, a well-characterized mechanism-based inhibitor of glutamine
synthetase and other enzymes, has a striking and unexpected effect of increasing survival in the
LPS/D-GalN mouse model for ALF. It prevents the activation of caspase-3 and furthermore
significantly reduces the overall inflammatory immune response as measured by reductions in
the levels of plasma cytokines, and it prevents the ensuing activation of caspase-3 and apoptosis
induction in hepatocytes. Of particular interest is that levels of TNF-α and IL6 are reduced one
hour after LPS/D-GalN treatment, indicating that the primary target of MSO is some step very
early in the immune response, most likely in the alteration of macrophage/Kupffer cell
activation.
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Determining the relative importance of these mechanisms in the suppression by MSO of
TNF-α and cytokine production will require further studies focusing on macrophage/Kupffer
cells and their environment, but it is clear that MSO, with its highly specific target, and at nontoxic doses, can efficiently rescue mice exposed to lethal doses of LPS/D-GalN. Glutamine
synthetase may therefore warrant additional attention as a new drug target in liver failure.
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CHAPTER-4
Methionine sulfoximine’s prevention of acute liver failure: understanding the involvement
of glutamine synthetase and glutamine

Introduction
Previous work from this lab has characterized the beneficial role of MSO in the extension
of life span in the SOD1 mouse model of amytropic lateral sclerosis (ALS). The studies
described in this thesis show that the use of MSO therapeutically in the mouse model for ALF
leads to a decrease in plasma cytokines – mainly TNF-α, IFN-γ, and IL-6 - and an increase in
survival by 75%. MSO inhibits the enzyme glutamine synthetase (GS). Glutamine, which is
produced by GS, is considered essential for the generation of cytokines. It also plays an
important role in immune cell proliferation, differentiation and maturation (Newsholme 2001).
Hence, the simplest explanation for MSO’s effects on ALF mouse model is its ability to inhibit
glutamine production and subsequently reduce the immune response. Our studies aim to
understand the effects of MSO and by extension the role of GS on inflammation in vitro and in
vivo. In this chapter we initiated experiments aimed at defining the mechanism of action of
MSO-induced GS inhibition on our ALF mouse model.
The experiments described in the previous chapter established that MSO prevents LPS/DGalN induced liver failure via its inhibitory action on inflammation. Two of the key modulators
of cell fate - TNF-α and IFN-γ – are reduced by more than 50% with MSO pre-treatment. The
plasma TNF-α and IFN-γ values explain the downstream effects of the inflammatory apoptotic
pathways seen in this disease (i.e. caspase-3 and STAT1 activation is prevented by MSO pretreatment). However, these anti-apoptotic effects do not fully explain the cellular mechanism

84

involved in MSO’s prevention of ALF. This chapter describes our subsequent efforts to explore
the effects of MSO on GS and TNF-α at early disease stage – i.e. 1 or 2 hours post disease
induction. We tested the effects of MSO treatment on TNF-α and GS transcription, on plasma
levels of glutamate and glutamine, and on macrophages and GS protein in liver tissue from mice.
For disease induction, we continued to use E coli lipopolysaccharides (LPS) and sugar DGalactosamine (D-GalN). We also investigated the cellular implications of glutamine level
variation and GS inhibition by MSO on isolated primary peritoneal macrophages. We measured
total protein synthesis in LPS-stimulated macrophages in the presence and absence of MSO
treatment.

Materials and Methods
Animals:
6 – 8 week old male CD1 animals were obtained from Charles River. Animals were
housed in Wayne State University and cared using the criteria outlined in the "Guide for the Care
and Use of Laboratory Animals" prepared by the National Academy of Sciences and published
by the National Institutes of Health (NIH publication 86-23 revised 1985). All experiments were
approved by the Animal Investigation Committee of Wayne State University.
Animals were starved overnight before the experiment. Control animals were injected
with saline and after 3 hours another saline injection was administered intra peritoneally (IP).
Diseased group animals were injected with saline, and after 3 hours, a mixture of LPS (20 µg/kg
body weight, sigma – LPS from E. Coli 0111:B4 Sigma #L2630) and D-GalN (800 mg/kg body
weight, Sigma #G1639) was administered. The treatment group consisted of mice injected with
MSO (50 mg/kg body weight, Sigma #M5379) three hours prior to LPS and D-GalN
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administration. All solutions were prepared in saline and administered IP. Since our previous
work showed TNF-α peaking at 1 hour post LPS/D-GalN administration, we studied samples
taken 1 hour or 2 hours after disease induction.
Western Blotting:
Liver homogenates were prepared from male mice either 3 hours after saline or MSO
injections (time zero controls) or at one hour time after IP administration of LPS/D-GalN. Liver
was homogenized in the presence of protease inhibitors. The homogenization buffer was made
up of 150 mM KCl, 5 mM β-mercaptoethanol and 1 mM EDTA. Livers were homogenized by a
mechanical rotor and centrifuged for 5 minutes at 10,000 x g - 4°C. Coomassie plus protein
assay (Thermo Scientific #1856210) was used to determine the protein concentration. 10µg of
protein extract was loaded for each sample. The supernatant extracts were boiled for 5 minutes
and identical protein amounts were separated on a 12.5% by SDS-PAGE and immunoblotted for
glutamine synthetase using anti-GS antibody (Sigma #G2781). Anti- GAPDH antibody (Sigma
#G9545) was used as a loading control.
IHC:
Liver was collected and cut into small 5mm sections which were frozen immediately in
OCT compound. The frozen tissue was stored at – 80oC when not in use. 10 micron sections
were cut in a microtome cryostat and loaded onto poly-lysine coated slides. The cut sections
were also stored at – 80oC.
For staining, the tissue sections were brought to room temperature for 30 minutes and
then fixed in ice cold acetone for 10 minutes. Thereafter the tissue was blocked in 10% BSA
(made up in phosphate buffered saline (PBS – pH 7.4) with 0.5% Tween 20 for an hour. The
tissue was incubated overnight in primary antibody at concentration of 1:100 and secondary
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antibody at concentration of 1:100 for 1hr. All antibodies were prepared in 1% BSA solution
made up in PBS – pH 7.4. Anti-glutamine synthetase antibody (Sigma #G2781) was used to
identify hepatocytes expressing GS and anti F4 80 antibody (e-biosceince #14-4801-81) was
used to stain for Kupffer cells. Secondary antibody of anti rabbit – HRP (Bio-Rad #170-6515)
was used against anti GS and anti rat – HRP (ebiosceince #18-4818-82) was used against F4 80
antibody. Slides were washed in for 5 minutes in PBS 3 – 5 times between each step. Lastly, the
tissue was exposed to 3’, 3’ – D, aminobenzidine tetrahydrocholride hydrate (DAB, Sigma
#D5637) solution prepared in 0.1M tris – pH 7.2, and 0.3% hydrogen peroxide. After color
development the sections were dehydrated in sequentially increasing concentrations of ethanol
and mounted with coverslips using permount (Fisher chemicals #FL-10-0505) mounting
medium.
Determination of plasma glutamate and glutamine:
Up to 1ml of blood was collected from anesthetized mice following cardiac puncture and
transferred to heparinized tubes (BD Microtainer tubes). Plasma obtained was transferred to ice
immediately and treated to remove all proteins. 10% (v/v) perchloric acid was added to plasma at
1:1 concentration and then the solution was centrifuged at 3000Xg for 3 minutes. The protein
precipitate was discarded and supernatants were neutralized with 20% (w/v) KOH in the
presence of a universal pH indicator. The solution was left on ice for 10 minutes and then
centrifuged again at 3000Xg for 3 minutes. The precipitates were again discarded and 250µl of
supernatant was used for the glutamine – glutamate determination (method based on protocol
from Lund P., 1986). L-glutamine and L-glutamate from protein-free plasma were quantified
using the manufacturer’s protocol for enzymatic determination of glutamine and glutamate (the
GLN-1 kit from Sigma-Aldrich was used)
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RNA isolation and RT-PCR:
Liver tissue was obtained from mice and stored in RNAlater solution (Qiagen #76154).
RNA was isolated using the manufacturer’s protocol for the RNeasy mini kit (Qiagen #74104).
The amount of RNA was quantified spectrophotometrically by measuring the absorbance at 260
nm and 280 nm. 1 µg of RNA was used to set up a reverse transcriptase reaction and form cDNA
using Quantitect reverse transcriptase kit (Qiagen #205311). 2 ul of cDNA was then used to set
up the qRT-PCR reaction using the quantifast SYBR green PCR kit (Qiagen #204054). Each
reaction was set up in triplicates. The RT-PCR reaction consisted of melting at 95°C for 15
seconds, annealing at 60°C for 30 sec and extension at 72°C for 15 sec. 40 cycles were run and
Ct values were obtained. Mouse gene specific TNF-α, GS, GAPDH and actin primers were
obtained

from

Qiagen

(quantitect

primer

assay,

Mn_Tnf1_1_SG

#

QT00104006;

Mm_Actb_2_SG # QT01136772; Mm_Glut_1_SG # QT01062306; Mm_Gapdh_3_SG #
QT01658692) . Actin expression was used as a control for GS and GAPDH was used as a control
gene for TNF-α.
Cell culture:
All cell culture experiments were done using peritoneal macrophages obtained from male
CD1 mice. Mice were euthanized in a CO2 chamber and transferred to a cell culture hood. The
peritoneum was injected with 10ml of cell culture medium RPMI with glutamine (RPMI with
glutamine - 2 mM) containing 10% FCS and 1% penicillin and streptomycin solution. The
peritoneum was massaged gently for 5 minutes, and the medium was extracted from the
peritoneum and centrifuged. The cell pellet obtained was re-suspended in 3 ml of RPMI with
glutamine. Cells were counted and 2 ml of cells were plated in 6-well plates at the density of 2 X
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104 cells/ml. The cells were transferred to 37oC – 5% CO2 incubator for 4 hours. Thereafter they
were washed three times with RPMI, and 2ml of fresh RPMI w or w/o glutamine was added. The
cells were again transferred to the 37oC – 5% CO2 incubator for 16 hours. Cells were washed the
next day with RPMI, and thereafter the experiments were started.
After 16 hours of overnight incubation, peritoneal macrophages were incubated in 1ml of
RPMI with or without glutamine. The medium was made up of 10% FCS and 1%
penicillin/streptomycin. The negative control well was not treated with LPS and/ or MSO. In the
positive control well 1µg/ml of LPS was added and in another MSO control well 9mM MSO was
added. The treatment wells had both 1mg/ml LPS and 9mM MSO added at the same time. Cells
were then transferred to 37oC – 5% CO2 incubator for the duration of the experiment – i.e. 4
hours. At the end of the experiment the cell culture medium was collected and frozen
immediately on dry ice and transferred to -20oC. The same treatment conditions were used for
radioactive protein measurements.
TNF-α Elisa:
TNF-α ELISA kits were obtained from ebioscience, and experiments were performed
using manufacturer’s guidelines for 96-well plate experiments. Each well contained 50µl of cell
culture medium mixed with 50 µl of blocking buffer. The TNF-α ELISA assay had a sensitivity
of 8-1000 pg/ml.
Protein synthesis measurement in cells and medium:
The peritoneal macrophages were incubated in 1ml of RPMI with glutamine. At the start
of the experiment 50µCi of S35 labeled cocktail of methionine and cysteine was added to the
medium. Samples were collected at 0, 1, 2, 4, 6, and 8 hours after S35, LPS, and/ or MSO
addition.
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For secreted protein measurements, 50 µl of medium was used. For cellular protein
synthesis measurements, PBS was added to cells, and then they were scraped and collected. To
cells as well as medium 10 ml of 10% TCA was added and tubes were incubated on ice for 10
minutes. TCA precipitated protein was filtered through glass fiber filter paper. The filter papers
were rinsed twice with 10 ml of 10% TCA. Filter papers were dried and TCA-precipitated counts
of S35 labeled proteins were measured in a scintillation counter.

Results:
Effect of MSO on Glutamine synthetase:
Figure 4.1A shows immunohistochemical staining of liver tissue sections obtained from
a control mouse (saline treated), LPS/D-GalN mouse (2 hours post disease induction) and MSO
pretreated LPS/D-GalN mouse (2 hours post disease induction). The 10 micron slices observed
here under 10X magnification show a section of the stained tissue. The control tissue shows
defined staining of perivenous hepatocytes, which is the known location of glutamine synthetase
in the liver. As expected, the hepatic parenchyma surrounding veins in the liver are stained dark
brown. Similar staining is seen in LPS/D-GalN tissue and MSO – LPS/D-GalN tissue section.
The amount of staining is visibly reduced in both MSO treated and untreated disease groups as
compared to the saline alone control tissue. However, there is no obvious change in the extent or
distribution of GS with and without MSO treatment. The negative control section was exposed to
only secondary antibody (no primary antibody exposure) during the staining procedure, and
shows no GS staining.
Figure 4.1B shows western blots obtained from liver tissue homogenates of treated and
untreated tissue. We have found that glutamine synthetase forms higher molecular weight
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aggregates when treated with MSO, which is observed in all non-boiled samples from MSO
treated tissue. These aggregates are broken down, and the normal molecular weight GS band is
seen when the tissue samples are boiled at 100 oC for 5 minutes. A western blot with boiled
tissue samples from MSO treated and untreated LPS/D-GalN exposed mice is shown in figure
4.1C. The blots show that there are no differences in the GS protein levels in treated and
untreated disease tissue collected from animals at 3 hours, 4 hours and 5 hours after disease
induction. We have not pursued the question of GS aggregation in the presence of MSO,
although the same phenomenon has been observed by another laboratory (Rao and Meister
1972).
Figure 4.1D shows the results of using real time – PCR to quantify the transcript levels
of GS. The saline control group transcripts were considered baseline, we can see a very small
fold change – 1.5 fold increase – in transcript levels of GS for LPS/D-GalN (1 hour post disease
induction) and MSO control tissue. There is also a very small change – 0.7 fold reduction – in
transcript levels in MSO treated tissue (1 hour post disease induction). Considering the apparent
importance of GS in this model, these changes in transcript levels within various groups may
have an implication in how MSO prevents liver failure. However, the changes are very small and
are not explained by the effects of this drug on enzyme activity.
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Figure 4.1. Effects of MSO treatment on protein and transcript levels of GS. Figure 1A
shows immunohistochemical staining of liver tissue sections observed under 10 X and 63 X
magnifications. The first panel is a control section stained with secondary antibody. It was not
exposed to primary antibody. Tissue sections from saline treated control liver, 2 hours LPS/DGalN treated liver, and MSO pre-treated 2 hour LPS/D-GalN treated liver show the characteristic
perivenous GS stained hepatic cells. The same results were observed in tissue collected from 3
different animals for each group. 6 sections were stained from each tissue sample. Figure 1B
shows western blots of non-boiled liver homogenate samples blotted for GS. Tissue
homogenates were prepared at one hour time intervals after LPS/D-GalN administration. GS
protein amounts are similar in all samples. MSO treatment leads to formation of higher
molecular weight aggregates of GS. These aggregates are lost upon boiling the samples before
running SDS-PAGE. Figure 1C shows western blots of liver homogenates blotted for GS. The
samples collected at 3hr, 4hr and 5hr after LPS/D-GalN administration were boiled for 5 minutes
and thereafter run of SDS-PAGE. The higher molecular weight bands of MSO pre-treated
samples are not present in boiled samples. The controls in all the blots consisted of tissue
collected from animals treated with saline for 3 hours for LPS/D-GalN exposed mice and
animals treated with MSO for 3 hours for MSO-LPS/D-GalN exposed mice. Figure 1D shows
the transcript levels observed in liver tissue from mice treated with saline alone or MSO alone
(controls – first and third bars in the graph) or mice exposed to LPS/D-GalN for 1 hour after
saline or MSO administration (second and fourth bars in the graph). Each 1 hour treatment group
has 5 animals and each control group had 3 animals. Using the house keeping gene GAPDH, fold
change in GS transcripts was calculated. Here, the Ct values obtained for GS were normalized to
those of GAPDH (to obtain ΔCt). Thereafter, the sample ΔCt values were normalized to LPS/DGalN control group (to obtain ΔΔCt). The values thus obtained were converted from log scale to
the linear scale (2^-ΔΔCt). The error bars are obtained from Standard error of mean of GS ΔCt
values. There is a 1.5 fold increase in GS transcripts in MSO treated control tissue and saline
treated LPS/D-GalN 1 hour treated liver. However, a slight decrease of 0.7 fold is observed in
MSO pre-treated 1 hour LPS/D-GalN treated liver.
MSO’s effect on Kupffer cells:
TNF-α is secreted primarily by macrophages, and in this liver failure model, Kupffer
cells are known to play a very important role (Karlmark, Wasmuth et al. 2008; Dong, Zuo et al.
2009; Leber, Mayrhauser et al. 2009). We looked at the Kupffer cells in the treated and untreated
tissue at 2 hours post disease induction. By this time, TNF-α level had peaked in plasma and
hence any abnormality with Kupffer cell numbers would be visible. In Figure 4.2, Kupffer cells
stained with F4 80 antibody can be seen in saline control, LPS/D-GalN and MSO – LPS/D-GalN
tissue sections. F4 80 is a marker for all types of macrophages. Control tissue exhibits well
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defined Kupffer cells which are evenly distributed evenly across the entire section. Treated and
untreated tissue shows fuzzy Kupffer cell staining which might be indicative of active Kupffer
cells undergoing a morphology change. However, there seems to be no difference within MSO
treated and the diseased tissue. Hence, MSO does not appear to affect Kupffer cell activation or
numbers in this ALF mouse model.
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Figure 4.2. Effects of MSO treatment on macrophage staining in liver tissue. This figure
shows immunohistochemical staining of liver tissue sections observed under 10 X and 40 X
magnifications. Here Kupffer cells were stained with antibody marker called F4/80. This
antibody stains for all macrophages. The first panel is a control section stained with secondary
antibody. It was not exposed to primary antibody. Tissue sections from saline treated control
liver, 2 hours LPS/D-GalN treated liver, and MSO pre-treated 2 hour LPS/D-GalN treated liver
show the macrophages present throughout the liver parenchyma. The saline control tissue show
distinctly shaped macrophages, whereas with LPS/D-GalN treatment the macrophages seem to
be activated and do not show a distinct morphology. The same is seen in MSO pre-treated
LPS/D-GalN treated liver section. The same results were observed in tissue collected from 3
different animals for each group. 6 sections were stained from each tissue sample.

MSO treatment reduces plasma glutamine but does not affect plasma glutamate:
Plasma was collected from mice 1 hour post disease induction, and plasma glutamate and
glutamine were quantified (Figure 4.3). Each group consisted of 4 animals. As shown in Figure
4.3A, plasma glutamate values for saline and MSO control animals were 320 ± 46 µM and 240 ±
54 µM respectively. 1 hour post disease induction, these values were elevated to 800µM and 760
± 57 µM respectively. These changes from control time point (i.e. 0hrs) to 1 hour for both
diseased and MSO pre-treated animals is significant (p=0.001 for both groups). However, it is
interesting to note that MSO does not in any way affect the plasma glutamate levels in these
animals. The fluctuations seen in glutamate after disease induction is significant and MSO
independent.
Figure 4.3B, shows the changes occurring in plasma glutamine. In control LPS/ D-GalN
animals at time zero, glutamine values were 680 ± 264 µM. Glutamine was slightly elevated to
800 ± 162 µM/L at 1 hour after LPS/D-GalN administration. With MSO pre-treatment, animals
exhibited much lower plasma glutamine. MSO control animals had plasma glutamine values of
68 ± 48 µM, which increased to 200 ± 57 µM at 1 hour post disease induction. Glutamine
changes between saline control and LPS/D-GalN treatment and MSO control and MSO –
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LPS/D-GalN treatment group are insignificant. However, the differences seen between control
saline and control MSO; and 1 hour saline and 1 hour MSO are significant (p = 0.019 and p = 0.
0.0025)

Figure 4.3. Plasma glutamate and glutamine levels in ALF mice. Figure A shows glutamate
levels determined in plasma from saline control, MSO control, LPS/D-GalN and MSO pretreated LPS/D-GalN treated animals. Each groups consisted of 4 animals. Plasma was collected
one hour after LPS/D-GalN administration. Plasma glutamate levels increased from 300μM of
plasma (saline control) and 240 μM of plasma (MSO control) to 800 μM of plasma (LPS/DGalN) and 760 μM of plasma (MSO – LPS/D-GalN). This increase in plasma glutamate one hour
after liver failure induction is significant for both MSO treated and untreated groups (p = 0.001).
Figure B shows plasma glutamine levels of the above mentioned four groups of animals. MSO
control animals exhibited low levels of glutamine in plasma 68 μM of plasma as compared to
saline control animals which had 680 μM of plasma. This reduction due to MSO treatment was
statistically significant (P=0.02). Similarly plasma collected from animals one hour post LPS/DGalN administration had 800μM glutamine, compared to MSO pre-treated LPS/D-GalN treated
animals (200μM glutamine). This difference was also statistically significant (p = 0.003). All the
p values were calculated using an unpaired t test.
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Effect of MSO on TNF-α transcript:
Figure 4.4 shows the fold change in the transcript levels of TNF-α in liver tissue from
LPS and MSO-treated mice. The MSO – LPS/D-GalN control group had the same transcript
levels as LPS/D-GalN control group. Transcripts increased by 100 ± 0.9 fold for LPS/D-GalN
treated animals and 115 ± 0.54 fold for MSO – LPS/D-GalN treated animals at one hour after
disease induction. (Values are represented as fold change ± SEM of ΔCt). These results show
that the TNF-α transcript increased by more than 100 fold post disease induction. Here we see no
significant difference in transcript levels when mice were pre-treated with MSO. Therefore,
MSO treatment does not affect TNF-

ion.

Figure 4.4. Effect of MSO treatment on TNF-α transcript levels. This figure shows the
transcript levels observed in liver tissue from mice treated with saline alone or MSO alone
(controls) or mice exposed to saline or MSO and treated with LPS/D-GalN for an hour. Each 1
hour treatment group had 5 animals and each control group had 3 animals. We calculated the
fold change in TNF-α transcripts relative to the transcript of the housekeeping gene actin, so the
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Ct values obtained for TNF-α were normalized to those of actin to obtain ΔCt. Thereafter, the
sample ΔCt values were normalized to LPS/D-GalN control group (to obtain ΔΔCt). The values
thus obtained were converted from log scale to the linear scale (2^-ΔΔCt). The error bars
represent the standard error of mean of TNF-α ΔCt values. There is a 100 and 115 fold increase
respectively in TNF-α transcript in tissue from MSO untreated and treated mice exposed to
LPS/D-GalN to 1 hour.
Effect of glutamine on TNF-α secretion:
MSO reduces both liver glutamine synthetase activity and plasma glutamine in animals 1
hour post LPS/D-GalN administration, suggesting that the synthesis of glutamine, or the
presence of glutamine, plays a role in the production of TNF-α. Chapter 3 shows that MSO
treatment at the same time as LPS addition resulted lead to a 18% average decrease in TNF-α
production (the decrease ranged from 8% to 37% (p=0.0017) in six separate experiments). In
these experiments, cells were incubated in glutamine during the overnight incubation phase (16
hours) after cell isolation and during the LPS or LPS+MSO treatment (4 hours) phase. Hence, we
conducted an experiment to test the effects of glutamine variation on TNF-α secretion by
primary peritoneal macrophages.
Each experiment consisted of two negative controls – treatment 1 consisted of untreated
cells and treatment 2 consisted of cells treated with 9mM MSO alone. Treatment 3 consisted of
cells exposed to 1 μg/ml of LPS and treatment 4 consisted of cells exposed to both 1 μg/ml of
LPS and 9 mM MSO. Cells were exposed to the above mentioned four conditions for 4 hours,
with the time of LPS and/or MSO addition being considered as time zero.
Each experiment was repeated six times, and the results are presented in Table 4.1. When
cells were incubated overnight in the presence of glutamine and then in the absence of glutamine
for the 4 hours during LPS treatment (condition 2 in Table 4.1), they exhibited an average
decrease in TNF-α production of 10% with a range of 7% to 15% with MSO treatment (p =
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0.04). When glutamine was absent from the culture medium throughout the experiment
(condition 3 in Table 4.1), MSO treatment reduced production of TNF-α by an average of 14%
(with a range of 6% to 27% - p=0.0055). Lastly, MSO treatment reduced TNF-α production by
1.8% (average) during condition 4 – no glutamine in cell culture medium during the 16 hour
overnight incubation and 2 mM glutamine present during the 4 hours of LPS treatment. The
fourth condition exhibited the most variation. In three out of six experiments, MSO treatment
increased TNF-α production by 4%, 2.5% and 7.5% and in three experiments it led to a decrease
of 12.5%, 4.3% and 7.5%. Averaging all the values gave a low average of 1.8%. Appendix 1
shows the TNF-α value in pg/ml for each of the six experiments done for the four glutamine
conditions.
4 hours after

16 hour

4 hours of LPS

% reduction in TNF-α

macrophage

overnight

and/ or MSO

production caused by

isolation

incubation

exposure

MSO treatment

1

+

+

+

8 – 37

2

+

+

_

7 – 15

3

+

_

_

6 -27

4

+

_

+

(-7.5) – 12.5

Glutamine
conditions

Table 4.1. The table describes the glutamine conditions to which cells were exposed. After
peritoneal macrophage isolation cells were plated in presence of 2 mM glutamine-rich RPMI
medium for 4 hours. Thereafter for 16 hours of overnight plating, cells were exposed to
glutamine rich RPMI medium for the first two conditions (condition 1 and 2), whereas cells
described in condition 3 and 4 were exposed to RPMI medium with no glutamine in it. During
the 4 hours of the experiment (i.e. after the addition of 1 µg/ml LPS and/or 9 mM MSO) cells of
condition 1 and 4 were exposed to glutamine rich cell culture medium and cells of condition 2
and 3 were incubated in RPMI with no glutamine. Thereafter, TNF-α was measured in the cell
culture medium using an ELISA. Six separate experiments were carried out. Values are
presented as % TNF-α production, comparing cytokine produced in the absence of MSO to that
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produced in the presence of MSO in LPS stimulated cells. TNF-α was below detection limits for
untreated and MSO alone treated cells. Under conditions of glutamine present throughout the
experiment (condition 1) or glutamine absent throughout the experiment (condition 3) we see a
statistically significant decrease in TNF-α production in cells treated with MSO and LPS as
compared to LPS alone. This decrease is of 8- 37% and 6 – 27% respectively. Whereas, when
glutamine is fluctuated during the experiment (conditions 2 or 4) the effect of MSO on TNF-α
secretion by peritoneal macrophages stimulated with LPS is either reduced (condition 2) or lost
altogether (condition 4). (The p values for all the experiments were calculated using paired t
test).
As described in Chapter 3 (and published) TNF-α production by peritoneal macrophages
is consistently reduced when cells are treated with MSO.

Here we show that modulating

exposure of cells to glutamine during the 16 hours overnight incubation and/or the 4 hours of
LPS treatment affect TNF-α production. Thus, the presence or absence of glutamine in the cell
culture medium can have an effect on TNF-α secretion by peritoneal macrophages. MSO has
maximal and consistent effect on cytokine production when the cells are exposed to high levels
of glutamine (condition 1) or no glutamine (condition 3) throughout the course of experiment.
We did not pursue this question further, and have therefore not tested any possible explanations
for these results. It may be that elimination of glutamine from the medium stimulates the
production of GS which might then reduce or negate the “effective MSO” concentration in these
experiments. But even though these results are difficult to interpret, it is clear that altering
glutamine levels can influence the extent of the effect of MSO on TNF-α production, supporting
the conclusion that glutamine presence/availability is involved in this effect.

Effect of MSO on protein production:
For these in vitro experiments, we used 9 mM MSO, which had been used in previously
published studies on the effects of MSO on cultured cells. To assure ourselves that this
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concentration was not having a global effect on protein synthesis, we measured total protein
synthesis in these cultures in the presence and absence of MSO. Figure 4.5A shows total
cellular protein synthesis in peritoneal macrophages, and figure 4.5B shows proteins synthesized
and secreted by cells into the cell culture medium, as measured by the incorporation of S 35
labeled methionine and cysteine. TCA-precipitable radioactive proteins were measured for 1)
control cells (untreated), 2) MSO (9 mM)-treated cells 3) LPS (1 µg/ml)-treated cells and 4) cells
treated with both MSO (9 mM) and LPS (1 µg/ml).
In control untreated cells, 20500 ± 3700 cpm of radioactive labeled protein was detected
at time zero. Incorporation of radioactivity increased linearly to 241900 ± 47300 cpm at 8 hours.
With MSO treatment, incorporation of radioactivity increased from 34000 ± 10200 cpm at zero
hours to 269800 ± 23700 cpm at 8 hours. In LPS-treated cells, the incorporation of radioactivity
from 19300 ± 4200 cpm at zero hours to 285600 ± 45700 cpm at 8 hours.. Treatment with both
LPS and MSO led to an increase in incorporation of radioactivity from 33300 ± 5300 cpm at
zero hours to 301700 ± 66600 cpm at 8 hours. Each experiment was conducted 3 times and the
results are presented as average ± SEM.
Similar results were observed for proteins secreted into cell culture medium. Here the
incorporation of radioactivity radio labeled proteins was measured in 50 µl of cell culture
medium and the results are shown in figure 4.5B. The control medium had 12100 ± 1900 cpm at
time zero. This increased to 76900 ± 11200 cpm after 8 hours. Medium obtained from MSO
alone and LPS alone conditioned cells had 14700 ± 2300 cpm and 15100 ± 5100 cpm at time
zero. At 8 hours the incorporation of radioactivity increased to 58200 ± 6500 cpm and 57800 ±
5300 cpm respectively. MSO treated cells exposed to LPS showed an initial incorporation of
radioactivity of 12600 ± 3900 cpm which increased to 41400 ± 12500 cpm at 8 hours. Appendix
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2 shows values obtained in CPM for all the experiments. Values for all time points are presented
for cellular protein as well as protein secreted in 50 µl of cell culture medium. Supernatant
samples from cells treated with MSO alone and LPS alone exhibited a slight reduction in radio
labeled protein being secreted into medium as compared to control cells. The cpm differences
observed at various time points in MSO and LPS treated cells and medium were not statistically
significant. These results indicated that 9 mM MSO does not affect protein production in cells
and has a negligible effect on total secreted protein levels. It is important to remember that
different genes are transcribed in resting and stressed cells. It is possible that MSO and LPS
together as well as separately might activate different genes without affecting overall protein
synthesis. Nonetheless, this experiment makes clear that 9 mM MSO does not have a global
inhibitory effect on protein synthesis in the presence of glutamine.
A – from cells
3.50E+05
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3.00E+05
2.50E+05
2.00E+05
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1.50E+05

mso
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1hr
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4hr
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Sample - time (hours)
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B - from medium
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Figure 4.5. Protein synthesis measurements in peritoneal macrophages exposed to LPS
and/ or MSO using radioactive S35. The figures show amount of incorporated S35 in newly
synthesized protein in untreated cells, cells treated with 9 mM MSO alone, cells treated with 1
μg/ml of LPS alone, and cells treated with 9 mM MSO and 1 μg/ml of LPS. Protein synthesis
was measured at 0hrs, 1hr, 2hr, 4hr, 6hr, and 8hr after LPS and/ or MSO addition. The blue line
shows S35 incorporation in untreated cells. The red shows S35 incorporation in MSO treated cells.
The green line shows S35 incorporation in proteins of LPS–treated cells and the purple line shows
protein synthesis in cells treated with both LPS and MSO. The results are the averages from
three separate experiments conducted on three different days. Results are presented as counts per
minute (CPM) of radioactive S35 incorporated in newly synthesized protein. All counts per
minute (CPM) values are given as mean ± standard error of mean. Figure 4.5.A shows total
protein synthesis in cells plus supernatant, Figure 4.5.B shows protein synthesis of cell secreted
proteins (culture supernatant).

Conclusion
Acute liver failure is defined as the deterioration of liver function over a short period of
time – typically a few weeks. Brain edema, a complication of ALF, first implicated ammonia and
glutamine metabolism in disease pathology. ALF can be induced in mice by intra peritoneal
administration of E. coli lipoplysaccharides (LPS) and the sugar D-Galactosamine (D-GalN).

104

The previous chapter focused on understanding the action of methionine sulfoximine (MSO) in
preventing liver failure. MSO increases survival in this ALF mouse model. MSO treatment
prevents caspase-3 and STAT-1 activation. MSO reduces the inflammatory immune response at
some very early step, prior to TNF-α production. TNF-α is one of the first acute phase proteins to
be secreted in ALF, and MSO reduces its production by more than 50% in the mouse model.
TNF-α was secreted as early as 1 hour post LPS and D-GalN administration. Since MSO is a
known irreversible inhibitor of glutamine synthetase (GS), GS and/or glutamine appear to be
involved in ALF-associated immune response. Kupffer cells – the resident liver macrophages –
have intrinsic GS activity and the GS transcripts are known to increase during stress ((Bode,
Peters-Regehr et al. 2000)). Moreover, glutamine is required for the generation, propagation, and
maintenance of the immune response (Crawford and Cohen 1985; Hörig, Spagnoli et al. 1993;
Li, Yin et al. 2007).
In this chapter we explored the mechanistic action of MSO. We first used
immunohistochemistry to determine the effects of MSO on glutamine synthetase and Kupffer
cells. 2 hours after disease induction the MSO-treated and untreated tissue did not exhibit any
differences in GS and Kupffer cell staining. GS staining was reduced in both LPS/D-GalN and
MSO – LPS/D-GalN tissue as compared to tissue collected from a saline-treated control animal.
This is indicative of a reduction in number of perivenous hepatocytes. Macrophages in both
treated and untreated tissue were diffusely stained compared to control tissue. This is indicative
of active macrophages. However, the staining patterns for MSO treatment and disease tissue
were similar. Hence, MSO does not appear to exert its beneficial effects via GS protein levels or
by directly acting upon macrophages.
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Since TNF-α levels reach maximal amount after one hour in plasma, we also examined GS
transcript levels and TNF-α transcript levels in tissue collected one hour after LPS/D-GalN
administration. Negligible TNF-α transcripts were detected in both saline treated and MSO
treated control animals (no LPS/D-GalN). In LPS/D-GalN-treated animals, MSO-treated and
untreated tissue exhibited 100 fold and 115 fold increases respectively. On other hand, GS
transcript levels increased by 1.5 fold in liver tissue from LPS/D-GalN tissue as compared to
liver tissue from saline treated mice. Control tissue from MSO treated mice also showed a 1.5
fold increase in transcript levels, and tissue from MSO treated LPS/D-GalN mice showed a 0.7
fold decrease. Since the fold changes in transcript amounts are quite small, much smaller than
the effect of MSO on the enzymatic activity of GS, MSO’s mechanistic effects – reduction in
TNF-α secretion in plasma of LPS/D-GalN treated mouse – probably does not involve alterations
in GS transcript levels at one hour after disease induction. MSO treatment clearly does not affect
TNF-α transcript but might have a small effect on the GS transcription.
At this point, we can summarize the in vivo experiments as follows:
1) MSO treatment reduces TNF-α in plasma (chapter 3)
2) MSO does not affect GS protein levels in liver sections
3) MSO does not affect macrophages – Kupffer cells – in liver sections
4) MSO does not affect TNF-α transcript levels and might have a very small effect on GS
transcript levels in LPS-treated mice.
MSO’s inhibition of GS had no effect on protein levels or transcription in vivo. MSO or
glutamine must therefore affect either translation or secretion of TNF-α and perhaps other
proteins. To investigate this question we conducted in vitro experiments using a cell culture
model of primary peritoneal macrophages. Protein production in macrophages stimulated with
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LPS in the presence or absence of MSO was measured by radioactive incorporation of S 35.
Protein synthesis within cells as well as secreted proteins in medium was monitored for up to 8
hours after LPS stimulation. MSO and LPS did not affect total protein production in cells.
However, different proteins might have been produced in resting untreated cells and LPS and/or
MSO treated cells.
TNF-α secretion by peritoneal macrophages was then measured in cell culture medium in an
experiment where cells were incubated with or without glutamine either during the 16 hour
overnight incubation phase before treatment or during the 4 hour LPS or LPS+MSO treatment
phase. Maximal inhibitory effect of MSO was observed in either presence or absence of
glutamine. When glutamine was either removed before the experiment or added during LPS
stimulation of cells or vice – a – versa MSO’s inhibitory effect was either lost or diminished.
There is no clear explanation for these results besides the observation that the effect of MSO
could be altered by altering culture medium glutamine.
At this point our results do not fully explain the role of glutamine and glutamine synthetase
in cytokine production by immune cells. Glutamine is involved in formation of other amino acids
and energy producing intermediates. Our model shows glutamine levels are depleted in the
plasma of MSO treated LPS/D-GalN injected mice. Work done by Komano et al, shows that
supplementing rat diet with 10% glutamine prevented serum transaminase elevation in D-GalN
induced liver injury. Serum transaminases are indicators of “liver health”. However, this 10%
glutamine supplementation was unable to prevent TNF-α and caspase-3 activation (Komano,
Yokoyama Funakoshi et al. 2009). Thus, it seems that glutamine is acting via some other
pathway to reduce cytokines and prevent caspase-3 activation.
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Glutamine is also required by various liver cell types for regeneration. Regeneration is
activated in stressed liver, and the ability of glutamine to form glutamate, glucosamine-6phosphate, GMP, NAD etc is critical (Gebhardt, Baldysiak-Figiel et al. 2007; Chang and Xu
2010). 90% of the energy required by liver parenchymal cells is obtained from glycolysis.
However, for Kupffer cells glutamine is the main source of energy (Spolarics, Lang et al. 1991).
Since glutamine is primary source of energy for immune cells, during stress it can become a ratelimiting factor for processes following proliferation – such as phagocytosis or antibody
production (Karinch, Pan et al. 2001), these and other processes involved in regeneration might
explain the mechanism of action of MSO. The reduction of glutamine might have no effect on
transcription within or proliferation of Kupffer cells, but might be having an effect on antibody
secretion and immune cell function triggered by liver damage. Such an explanation, however,
still does not tell us the exact mechanism by which MSO prevents the production of TNFAnother contradictory fact is that cytokine release is generally controlled at the level of gene
expression. Hence, intracellular signaling mechanisms which induce transcription of late and
early response inflammatory genes might be more important in this model. As mentioned in the
discussion of the previous chapter, β – catenin and mTOR pathways are involved with glutamine
metabolism. β-catenin mutated hepatic carcinoma cell lines are “addicted” to glutamine. βcatenin acts to inhibit apoptosis and glutamine synthetase is under its control (Bioulac-Sage,
Cubel et al. 2011). Depletion of glutamine pools by MSO in these cells initiates autophagy and
apoptosis. Whereas, in some cell lines MSO causes accumulation of glutamine within the cells
leading to mTOR activation and cell survival (Tardito, Chiu et al. 2011). Direct activation of
mTOR in cells by MSO has also been observed. Moreover this effect is more pronounced in
glutamine depleted cells (Tardito, Chiu et al. 2011). mTOR is a serine/ theronine protein kinase.
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It regulates cell proliferation, cell survival, transcription and translation. It has capacity to
integrate the nutrient status of cell with energy and redox status. It is especially sensitive to
glutamine. These two pathways might be influenced by MSO in our model of liver failure, and
by their action we see the protective effects of MSO being exercised.
Clearly these studies are just the beginning of understanding the therapeutic effects of
MSO in this mouse model of ALF. Further studies need to address the importance of signaling
pathways such as how the β-catenin and mTOR pathways respond in the presence MSO. At the
same time, glutamine’s actions need to be scrutinized at the levels of transcription, translation
and secretion. Glutamine compartmentalization within various liver cell types – specifically
periportal hepatocytes, pericentral hepatocytes and Kupffer cells – needs to be explored. The
current studies need to be elaborated to include tissue collected at more time intervals after
LPS/D-GalN administration. MSO’s effects on translation and protein secretion have to be
scrutinized to determine which step in TNF-

tion is most strongly affected. We need to

look at TNF-α secretion rather than total secreted proteins to determine MSO’s effect. Lastly,
while continuing the experiments with peritoneal macrophages it would be essential to remember
that the peritoneal macrophages are not Kupffer cells, and the specialized liver macrophages
might be involved in the disease progression by novel mechanisms.
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CHAPTER-5
Conclusion and future directions
The liver is an important organ, responsible for detoxification, protein synthesis,
glycogen storage, gluconeogensis, cholesterol synthesis, drug metabolism, production of
digestive juices, and ammonia detoxification. Acute liver failure (ALF) is a condition
characterized by development of coagulopathy and hepatic encephalopathy in a previously
healthy individual. ALF is caused by acetaminophen overdose, viral hepatitis (A, B and E),
autoimmune hepatitis, severe alcohol intake and idiosyncratic reaction to drugs such as
tetracycline. Severe systemic inflammation is mainly responsible for disease pathogenesis.
Resident immune cells generate multiple cytokines at the site of injury and inflammation.
Primarily macrophages i.e. Kupffer cells secrete cytokines which activate other immune cells in
the vicinity (i.e. PMNs, NK and NKT cells) and thereafter attract and activate systemic immune
cells, resulting in the generation of multiple cytokine and chemokines, hence the term cytokine
storm is often used to explain ALF associated inflammation. Multiple cytokines are capable of
initiating apoptotic death pathways in hepatocytes.
Methionine sulfoximine (MSO) is an irreversible inhibitor of glutamine synthetase (GS).
GS plays an important role in ammonia detoxification. It generates glutamine from glutamate
and ammonia. Glutamine is an energy source for immune cells. It is a conditionally essential
amino acid. During stress conditions glutamine becomes rate limiting for immune cells. Our
preliminary results show that inhibiting GS by treatment with MSO dramatically improved
survival in a mouse model of acute liver failure.
The aims of my project were to 1) characterize the mechanism of action of MSO on the
mouse model for acute liver failure (ALF) by screening for changes in plasma metabolites and
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signaling molecules associated with the steps involved in different death pathways, 2) identify
which step in the inflammatory response was inhibited by MSO treatment, and 3) to characterize
the mechanism of action of MSO on the inflammatory immune response. The previous chapters
have described the studies that answered aims 1 and 2, and have also described our first studies
toward addressing aim 3.
For this project we used a model of lipopolysaccharides (LPS) and D- galactosamine (DGalN) administration in mice. Our initial experiments were conducted on mice, but it was
necessary to study macrophages in vitro to address mechanistic questions, so we included
experiments on primary peritoneal macrophage cell culture to address how MSO might be
affecting the inflammatory immune response. The major conclusion from both in vivo and in
vitro studies is that the non essential amino acid glutamine and enzyme glutamine synthetase
(GS) appear to influence the disease process, and that inhibition of GS by MSO prevents ALF
associated inflammatory responses.
The inflammatory immune response that occurs during ALF involves the production of
many cytokines, the most prominent of which are TNF-α, IFN-γ and IL-6. These cytokines
activate death pathways by activation of caspase 3 and STAT1, both of which are capable of
causing cellular death by apoptosis. Inhibition of glutamine synthetase by pre-treating animals
with MSO both increased survival and prevented activation of caspase 3 and STAT1, in addition
to reducing the levels of most plasma cytokines tested, especially TNF-α and IFN-γ, both of
which were reduced by more than 50%.
In LPS/D-GalN treated animals, plasma glutamate levels were doubled but plasma
glutamine levels were unaffected one hour after disease induction. With MSO pre-treatment,
glutamate levels were same as control and were double at one hour after LPS/D-GalN injection.
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However, plasma glutamine levels were reduced by 80% in MSO treated animals for both
control and LPS/D-GalN treated group of animals. GS activity, observed from 1 hour to 5 hours
after disease induction, in MSO pre-treated livers was reduced by more than 90% compared to
livers from untreated animals, where activity did not fluctuate over the same 5 hours (result
shown in chapter 3). MSO pre-treatment did not affect TNF-α transcript levels which increased
100 fold one hour after LPS/D-GalN administration in both saline and MSO treated animals. At
the same time, a 1.5 fold increase was seen in GS transcripts of diseased and MSO control
animals. MSO treated disease animals exhibited a 0.7 fold reduction in GS transcript levels.
Therefore, MSO did not significantly affect the transcription of either TNF-α, which was
substantially elevated in LPS-treated animals, or GS, which was substantially unchanged in LPStreated animals.
I conducted immunohistochemistry experiments to see what effect MSO might be having
on total amounts of observable glutamine synthetase in normal and diseased livers, and also to
see if the total numbers of liver macrophages (Kupffer cells) were obviously altered by MSO
treatment. Both experiments showed no effect of MSO, so it appears that this drug does not
affect the amount of GS or the numbers of macrophages.
We conducted preliminary tests of the glutamine requirement for the TNF-α production
in cell cultures of peritoneal macrophages. Although MSO-treatment consistently reduced TNFα production in these cultures treated with LPS, that effect could be modified by the presence or
absence of glutamine in the culture. Detailed experiments with varying conditions of glutamine
during overnight cell incubation and treatment with LPS and/ or MSO produced conflicting
effects of MSO on TNF-α production. Keeping glutamine constant during the experiments i.e.
either conducting the experiments in presence of 2 mM glutamine and in complete absence of
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glutamine showed maximal MSO inhibition of TNF-α production in presence of LPS. However,
if glutamine in the medium was varied during the experiments, MSO’s effects were either
diminished or lost. Especially if glutamine was removed from cells until LPS and/ or MSO
addition, TNF-α production was unaffected or even increased in the presence of MSO for LPS
treated cells. These results are difficult to interpret, but they do show that glutamine levels in the
culture medium can affect the action of MSO on TNF-α production.
One control experiment that was easy to interpret was my investigation on the effects of
MSO on overall levels of protein synthesis, using S35-labelled methionine and cysteine to
quantitate the synthesis of both cellular and secreted proteins. In both untreated cells and cells
treated with LPS to induce a cytokine response, the presence of 9 mM MSO had no effect on
TCA-precipitable counts from either cells or the culture supernatant. Therefore, the effect of
MSO was not a global effect on cellular protein synthesis.
In summary, MSO does not affect transcription of GS or TNF-α. It does not affect
observable levels of GS in liver, and it does not affect the numbers of macrophages in liver. In
cell culture, 9 mM MSO does not affect protein synthesis, but its inhibitory effect on cytokine
production can be modulated somewhat by the presence or absence of culture glutamine – a not
unexpected result.
My studies have shown that some connection exists between glutamine synthetase and
the very early steps of the inflammatory immune response. That connection probably involves
glutamine levels, although these studies do not address the specific involvement of plasma
glutamine or some localized concentration of intracellular glutamine. As alluded to above, we
found that starving peritoneal macrophages for glutamine overnight made them resistant to the
cytokine-inhibitory effect of MSO when glutamine was added during the immune response, but
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cells fed glutamine overnight and then starved of glutamine during the immune response were as
sensitive to MSO as cells that had never been starved. Therefore, as we expected, glutamine
levels matter, but we still don’t know how.
The question of how GS is involved in the inflammatory immune response will have to
be addressed in the future. The initial experiments will confirm the involvement of GS in this
process by either 1) knocking down the expression of GS in peritoneal macrophages and
repeating the experiments in cells with no GS, or by using another macrophage cell line which is
capable of secreting TNF-α but does not have GS, or 2) using the liver specific GS knockout
mouse model (liver specific β – catenin knockout mouse model). We would predict that the
absence of GS in any of these systems would make these cells unable, or less able, to produce
cytokines when stimulated by LPS. If cytokines were produced in the absence (or reduction) of
GS, it would suggest that MSO might have one or more additional targets that are involved in the
cytokine response.
But if, as we expect, GS really is the functional target for MSO in this system, future
studies will involve a detailed analysis of cytokine synthesis and secretion, with the major
question being what effect does MSO treatment have on the translation and secretion/release of
TNF-α, arguably the most important inflammatory cytokine in this system as well as in many
others? We have shown that MSO does not affect transcription. We will address this question in
two ways – immunohistochemical and immunoprecipitate.

We will try to use

immunohistochemistry of liver slices to determine if the amounts of TNF-α produced in the
presence of MSO are similar to the amounts produced in the absence of MSO. If so, then the
results would support the hypothesis that MSO prevents release of TNF-α from the cells or cell
surfaces. If not, and we see a significant reduction in the anti- TNF-α fluorescence in slices from
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MSO-treated animals, then MSO is preventing synthesis of the cytokine, specifically by
inhibiting translation. However, these will be difficult experiments because it may be difficult or
impossible to visualize TNF-α in tissue slices. Or the amounts of intracellular TNF-α and
membrane-associated TNF-α might be too low to be analyzed by this approach. It may therefore
be necessary to use an immunoprecipitation approach using either mouse liver tissue or
peritoneal macrophages, or both.
In vivo, we could solublize liver homogenates from control animals, LPS-treated animals,
or LPS-treated animals pretreated with MSO, then attempt to immunoprecipitate those extracts
with anti-TNF-α, followed by immunostain analysis to determine if the presence of MSO
significantly reduced the total amount of TNF-α in the tissue. In vitro, we could label LPStreated cells with S35, then immunoprecipitate whole cells (solublized) and cell supernatant with
anti- TNF-α to determine if MSO treatment reduces the total amount of TNF-α produced in cells
treated with LPS. We hope these approaches will provide a more definitive answer to the
question of which step in the early immune response is affected by MSO treatment.
The subsequent studies to define the mechanism more exactly will depend on the results
of those experiments. We will either be studying the factors involved in TNF-α translation more
carefully to determine how they are affected by MSO, or we will be studying the processing and
release of TNF-α from the cell surface to see how that process is affected by MSO. As
mentioned above, it is possible – although we feel unlikely – that these studies will show that
MSO has another target involved in the inflammatory immune response besides (or in addition
to) glutamine synthetase, in which case we would try to identify that target.
The involvement in the response to LPS of neutrophils and natural killer T cells has also
been identified in this thesis. Their infiltration pattern in the presence and absence of MSO pre-
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treatment will be investigated by immunohistochemistry. It is possible that MSO prevents tissue
infiltration by other immune cells and thus prevents the cytokine storm. Another method of
studying the mechanism is to modify the disease model. The use of acetaminophen,
thioacetamide or chronic alcoholic liver failure model will provide diversity in terms of immune
response. Each model is perpetuated by a type of immune cell and the effect of MSO on a
specific type of immune cell within a whole animal can thus be easily studied.
Finally, there is a vast amount of research being carried out to understand the role of
glutamine in inflammation. In the previous chapters we described the involvement of the mTOR
-catenin pathways in glutamine metabolism. MSO treatment might be acting, in part, by
influencing one or both of those signaling pathways. Contradictory literature of glutamine’s
effect on cytokine production and immune cell proliferation is indicative of the complexity of its
role. Dietary glutamine is not necessarily beneficial in all conditions of stress. At the same time
compartmentalization of GS within the liver shows that it plays a bigger role than just ammonia
detoxification and glutamine homeostasis. Understanding these complex questions will involve
experiments building on the results of my studies to provide new directions in this research.
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APPENDIX A
Condition

Sample
Nil
MSO
LPS
LPS + MSO

Exp 1
BDL
BDL
495
421

Exp 2
BDL
BDL
548
442

Exp 3
BDL
BDL
491
394

Exp 4
BDL
BDL
361
228

Exp 5
BDL
BDL
654
604

Exp 6
BDL
BDL
610
564

2
Gln=+/+/-

Nil
MSO
LPS
LPS + MSO

BDL
BDL
742
682

BDL
BDL
117
102

BDL
BDL
1120
1046

BDL
BDL
759
701

BDL
BDL
118
110

BDL
BDL
1142
971

3
Gln=+/-/-

Nil
MSO
LPS
LPS + MSO

BDL
BDL
556
522

BDL
BDL
557
479

BDL
BDL
420
307

BDL
BDL
523
454

BDL
BDL
569
510

BDL
BDL
567
BDL

Nil
MSO
4
Gln= +/-/+
LPS
LPS + MSO

BDL
BDL
592
616

BDL
BDL
673
587

BDL
BDL
645
661

BDL
BDL
559
517

BDL
BDL
407
389

BDL
BDL
508
546

1
Gln=+/+/+

Appendix A. TNF-α values obtained from cultured primary peritoneal macrophages are
presented above. Cells were cultured in RPMI medium containing 5% FCS and in presence or
absence of 2 mM glutamine. 50 µl of cell culture medium was used for ELISA measurement of
the cytokine. Sensitivity of ELISA was 8 – 1000 pg/ml. Cells were stimulated with 1 µg/ml of
LPS for 4 hours and then the culture medium was collected for TNF-α production. Experiment
consisted of controls such as untreated cells and cells treated with 9 mM MSO alone. Both these
conditions produced undetectable amounts of TNF-α (BDL = below detectable limits). For cells
treated with LPS alone and LPS and MSO TNF-α values obtained are presented as pg/ml in the
above table. %decrease presented in table 4.1 of the thesis has been calculated from the above
shown values. Also, these values were used to run a paired t test and obtain the p values which
have been described in the chapter 4. This experiment shows that varying glutamine in cell
culture medium has an effect on TNF-α secretion.
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APPENDIX B
Experiment 1
Sample
Nil
MSO
LPS
LPS + MSO

0hr
13360
51449
11641
24824

1hr
56509
69374
50506
46553

2hr
88840
78617
89645
107817

4hr
111052
132651
188478
190337

6hr
206269
188186
228665
229813

8hr
236167
290040
247254
310109

Experiment 2
Sample
Nil
MSO
LPS
LPS + MSO

0hr
22068
16055
20004
43125

1hr
91301
91393
80160
84553

2hr
99267
127629
134466
163202

4hr
211055
209576
202575
252229

6hr
221853
327435
291853
350060

8hr
326559
296849
376599
412424

Experiment 3
Sample
Nil
MSO
LPS
LPS + MSO

0hr
26155
34532
26226
31991

1hr
33288
44529
74708
42390

2hr
99393
113086
100061
95352

4hr
112384
128350
131006
123756

6hr
157873
220429
159692
195092

8hr
163059
222511
233035
182560

Appendix B.1. CPM values obtained by TCA precipitation of radio labeled proteins from
cultured primary peritoneal macrophage cells. Three separate experiments are listed above.
20,000 cells were cultured in wells of a 6 well plate. Radioactive S 35, LPS and MSO were added
at the start of the experiment (0hr). At various time points (0hr, 1hr, 2hr, 4hr, 6hr and 8hr) after
S35, LPS and MSO addition medium was removed and cells were washed once. The cells were
then scraped in 500 µl of PBS and proteins were TCA precipitated with 10 ml of ice cold 10%
TCA. The precipitates were collected on glass fiber filter paper and washed twice with 10%
TCA. The filters were air dried and thereafter the radio labeled protein formed was measured in
cpm (counts per minute) in a scintillation counter.
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Experiment 1
Sample
Nil
MSO
LPS
LPS + MSO

0hr
15104
14786
6313
7005

1hr
23803
24733
22905
43854

2hr
29241
31218
28315
35292

4hr
32621
33867
35830
40658

6hr
34350
37230
28532
26428

8hr
99174
50428
47131
16627

Experiment 2
Sample
Nil
MSO
LPS
LPS + MSO

0hr
12695
10649
15236
10740

1hr
28083
25658
27489
22885

2hr
41462
35876
52434
42159

4hr
52622
50986
46280
47873

6hr
60008
68514
56241
53232

8hr
67434
53096
63535
57143

Experiment 3
Sample
Nil
MSO
LPS
LPS + MSO

0hr
8585
18678
23845
20110

1hr
16686
15240
15948
14214

2hr
26610
33754
39382
33474

4hr
79236
29724
41509
35675

6hr
50145
57038
54832
43666

8hr
64140
71057
62896
50543

Appendix B.2. CPM values obtained by TCA precipitation of radio labeled proteins from cell
culture medium of cultured primary peritoneal macrophage cells. Three separate experiments are
listed above. 20,000 cells were cultured in wells of a 6 well plate. Radioactive S 35, LPS and
MSO were added at the start of the experiment (0hr). At various time points (0hr, 1hr, 2hr, 4hr,
6hr and 8hr) after S35, LPS and MSO addition 50 µl of medium was removed and 10 ml of ice
cold TCA was added to it for protein precipitation. The precipitates were collected on glass fiber
filter paper and washed twice with 10% TCA. The filters were air dried and thereafter the radio
labeled protein formed was measured in cpm (counts per minute) in a scintillation counter.
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ABSTRACT
USE OF METHIONINE SULFOXIMINE TO DISSECT THE ROLE OF GLUTAMINE
SYNTHETASE AND GLUTAMINE IN PROGRESSION OF ACUTE LIVER FAILURE
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Methionine sulfoximine (MSO) is a modified amino acid and a well characterized
irreversible inhibitor of glutamine synthetase (GS) enzyme. Glutamine is synthesized by GS
enzyme and it is the most abundant amino acid in the body. Glutamine is required by immune
cells for generation, propagation and maintenance of an immune response.
To induce acute liver failure (ALF) in mice, animals were given intraperitoneal injections
of E. coli lipopolysaccharides (LPS) and sugar D-galactosamine (D-GalN). When these animals
were pretreated with MSO, 80% of the animals were completely rescued from liver failure.
Moreover, when we characterized the immune response generated during ALF using cytokine
antibody microarrays, we observed 1) that the macrophages and neutrophils appeared to be
responsible for the cytokine storm generated during ALF, and 2) MSO pretreatment reduced the
entire measured cytokine response.
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Using ELISA assays we observed that MSO pretreatment reduced plasma cytokine
values of TNF-α, IFN-γ and IL-6 by more than 50%. MSO inhibited GS by more than 90% in
liver extracts and reduced plasma glutamine by around 75%. MSO pretreatment had no effect on
GS protein levels and on kupffer cell (liver macrophages) infiltration in liver. GS and TNF-α
transcript levels were unaffected by MSO pretreatment. Also, preliminary results show that MSO
does not inhibit cellular and secreted protein synthesis globally in LPS stimulated peritoneal
macrophage cell culture. However, MSO treatment reduces TNF-α production in the LPS
stimulated peritoneal macrophages.
Thus, it seems that inhibiting GS during stress conditions such that low levels of plasma
glutamine are maintained can lead to a reduction in inflammatory cytokines. Also, MSO might
have targets other than glutamine synthetase. These results show a novel use for MSO in
attenuating the overall immune inflammatory response in liver.
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